| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 626 | 2025 | 5197 | 44.480 |
Why?
|
| Dexamethasone | 196 | 2025 | 1964 | 19.010 |
Why?
|
| Thalidomide | 153 | 2024 | 886 | 16.650 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 258 | 2025 | 11874 | 14.780 |
Why?
|
| Boronic Acids | 166 | 2024 | 915 | 13.390 |
Why?
|
| Pyrazines | 167 | 2024 | 1205 | 11.890 |
Why?
|
| Hepatic Veno-Occlusive Disease | 45 | 2021 | 220 | 11.670 |
Why?
|
| Polydeoxyribonucleotides | 36 | 2024 | 136 | 10.980 |
Why?
|
| Antineoplastic Agents | 210 | 2024 | 13658 | 6.840 |
Why?
|
| Boron Compounds | 25 | 2025 | 196 | 5.910 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 92 | 2024 | 5717 | 5.820 |
Why?
|
| Glycine | 25 | 2025 | 672 | 5.230 |
Why?
|
| Drug Resistance, Neoplasm | 101 | 2024 | 5335 | 4.900 |
Why?
|
| Neoplasm Recurrence, Local | 68 | 2024 | 9412 | 4.900 |
Why?
|
| Melphalan | 41 | 2024 | 421 | 4.850 |
Why?
|
| Hydroxamic Acids | 23 | 2017 | 483 | 3.950 |
Why?
|
| Salvage Therapy | 22 | 2021 | 1273 | 3.900 |
Why?
|
| Histone Deacetylase Inhibitors | 27 | 2021 | 777 | 3.800 |
Why?
|
| Protease Inhibitors | 48 | 2019 | 751 | 3.680 |
Why?
|
| Antibodies, Monoclonal | 55 | 2024 | 9253 | 3.490 |
Why?
|
| Recurrence | 101 | 2024 | 8507 | 3.130 |
Why?
|
| Phenylalanine | 12 | 2024 | 367 | 3.120 |
Why?
|
| Immunologic Factors | 33 | 2022 | 1595 | 2.890 |
Why?
|
| Disease-Free Survival | 74 | 2022 | 6843 | 2.790 |
Why?
|
| Stem Cell Transplantation | 34 | 2022 | 1596 | 2.690 |
Why?
|
| Fibrinolytic Agents | 17 | 2020 | 2080 | 2.620 |
Why?
|
| Peripheral Nervous System Diseases | 21 | 2021 | 716 | 2.410 |
Why?
|
| Hydrazines | 15 | 2024 | 223 | 2.340 |
Why?
|
| Transplantation, Autologous | 50 | 2024 | 2119 | 2.300 |
Why?
|
| Indoles | 15 | 2017 | 1835 | 2.290 |
Why?
|
| Humans | 833 | 2025 | 767998 | 2.180 |
Why?
|
| Maximum Tolerated Dose | 24 | 2024 | 897 | 2.070 |
Why?
|
| Triazoles | 18 | 2024 | 904 | 2.000 |
Why?
|
| Multiple Organ Failure | 13 | 2021 | 388 | 1.990 |
Why?
|
| Aged | 257 | 2025 | 171453 | 1.860 |
Why?
|
| Treatment Outcome | 190 | 2025 | 65360 | 1.820 |
Why?
|
| Clinical Trials as Topic | 59 | 2024 | 8052 | 1.730 |
Why?
|
| Middle Aged | 290 | 2025 | 223422 | 1.720 |
Why?
|
| Transplantation Conditioning | 16 | 2020 | 1601 | 1.660 |
Why?
|
| Survival Rate | 59 | 2021 | 12827 | 1.650 |
Why?
|
| Lactams, Macrocyclic | 13 | 2017 | 319 | 1.520 |
Why?
|
| Male | 338 | 2025 | 364638 | 1.510 |
Why?
|
| Drug Administration Schedule | 40 | 2021 | 4857 | 1.490 |
Why?
|
| Proteasome Endopeptidase Complex | 36 | 2022 | 1319 | 1.490 |
Why?
|
| Aged, 80 and over | 125 | 2025 | 59600 | 1.480 |
Why?
|
| Clinical Trials, Phase III as Topic | 19 | 2023 | 878 | 1.420 |
Why?
|
| Female | 338 | 2025 | 397102 | 1.400 |
Why?
|
| Leukemia, Plasma Cell | 5 | 2021 | 46 | 1.380 |
Why?
|
| Benzoquinones | 10 | 2012 | 198 | 1.380 |
Why?
|
| B-Cell Maturation Antigen | 6 | 2021 | 149 | 1.350 |
Why?
|
| Adult | 229 | 2025 | 223577 | 1.330 |
Why?
|
| Clinical Trials, Phase II as Topic | 21 | 2023 | 639 | 1.290 |
Why?
|
| Antineoplastic Agents, Alkylating | 6 | 2020 | 614 | 1.280 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 5 | 2021 | 179 | 1.240 |
Why?
|
| Angiogenesis Inhibitors | 21 | 2019 | 2055 | 1.220 |
Why?
|
| Lactones | 10 | 2020 | 316 | 1.110 |
Why?
|
| Apoptosis | 81 | 2021 | 9521 | 1.110 |
Why?
|
| Bone Marrow | 36 | 2021 | 2935 | 1.100 |
Why?
|
| Ubiquitin-Protein Ligases | 5 | 2024 | 1901 | 1.090 |
Why?
|
| Neoplasm Staging | 27 | 2024 | 11221 | 1.090 |
Why?
|
| Dose-Response Relationship, Drug | 62 | 2025 | 10757 | 1.080 |
Why?
|
| Phosphorylcholine | 9 | 2012 | 153 | 1.070 |
Why?
|
| Kaplan-Meier Estimate | 32 | 2021 | 6517 | 1.030 |
Why?
|
| Thrombocytopenia | 11 | 2024 | 1178 | 1.020 |
Why?
|
| Renal Insufficiency | 12 | 2023 | 812 | 1.000 |
Why?
|
| Neoplasm Proteins | 12 | 2021 | 3601 | 0.990 |
Why?
|
| Quality of Life | 20 | 2024 | 13489 | 0.980 |
Why?
|
| Oligopeptides | 11 | 2024 | 1194 | 0.970 |
Why?
|
| Drug Evaluation, Preclinical | 13 | 2020 | 1335 | 0.940 |
Why?
|
| Survival Analysis | 40 | 2024 | 10096 | 0.920 |
Why?
|
| Administration, Oral | 24 | 2023 | 4030 | 0.920 |
Why?
|
| Pyrroles | 11 | 2020 | 1123 | 0.910 |
Why?
|
| HSP90 Heat-Shock Proteins | 12 | 2015 | 422 | 0.910 |
Why?
|
| Diphosphonates | 11 | 2021 | 633 | 0.900 |
Why?
|
| Prognosis | 59 | 2024 | 29984 | 0.850 |
Why?
|
| Multienzyme Complexes | 12 | 2004 | 664 | 0.830 |
Why?
|
| Ikaros Transcription Factor | 1 | 2024 | 233 | 0.830 |
Why?
|
| Paraproteinemias | 2 | 2019 | 252 | 0.820 |
Why?
|
| Remission Induction | 26 | 2016 | 2409 | 0.800 |
Why?
|
| Randomized Controlled Trials as Topic | 25 | 2023 | 10396 | 0.780 |
Why?
|
| Cell Line, Tumor | 89 | 2024 | 17128 | 0.780 |
Why?
|
| Follow-Up Studies | 48 | 2024 | 39340 | 0.770 |
Why?
|
| Receptors, Immunologic | 6 | 2015 | 1418 | 0.760 |
Why?
|
| Waldenstrom Macroglobulinemia | 11 | 2016 | 1077 | 0.760 |
Why?
|
| Disease Progression | 40 | 2025 | 13667 | 0.750 |
Why?
|
| Receptors, CXCR4 | 4 | 2021 | 729 | 0.750 |
Why?
|
| Neutropenia | 8 | 2024 | 892 | 0.740 |
Why?
|
| Retreatment | 10 | 2024 | 598 | 0.740 |
Why?
|
| Receptors, OX40 | 1 | 2021 | 46 | 0.740 |
Why?
|
| NF-kappa B | 32 | 2021 | 2493 | 0.730 |
Why?
|
| Gene Expression Regulation, Neoplastic | 34 | 2021 | 8637 | 0.730 |
Why?
|
| Neoplasms, Second Primary | 6 | 2017 | 1061 | 0.730 |
Why?
|
| Imidazoles | 15 | 2015 | 1168 | 0.730 |
Why?
|
| GABA-B Receptor Agonists | 2 | 2017 | 11 | 0.730 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 204 | 0.720 |
Why?
|
| Bone Marrow Transplantation | 10 | 2021 | 2711 | 0.700 |
Why?
|
| Endothelial Cells | 10 | 2021 | 3589 | 0.680 |
Why?
|
| Proto-Oncogene Proteins c-akt | 17 | 2014 | 2456 | 0.680 |
Why?
|
| Molecular Targeted Therapy | 9 | 2024 | 2824 | 0.670 |
Why?
|
| Neoplasms, Plasma Cell | 4 | 2024 | 38 | 0.670 |
Why?
|
| Antibodies, Neoplasm | 1 | 2021 | 283 | 0.660 |
Why?
|
| Tumor Cells, Cultured | 58 | 2021 | 6119 | 0.660 |
Why?
|
| Platelet Aggregation Inhibitors | 6 | 2017 | 2764 | 0.650 |
Why?
|
| Vasculitis | 2 | 2021 | 526 | 0.640 |
Why?
|
| Doxorubicin | 22 | 2021 | 2234 | 0.630 |
Why?
|
| Endothelium, Vascular | 11 | 2024 | 4427 | 0.630 |
Why?
|
| Double-Blind Method | 31 | 2021 | 12464 | 0.620 |
Why?
|
| Osteonecrosis | 6 | 2015 | 230 | 0.620 |
Why?
|
| Membrane Glycoproteins | 9 | 2021 | 3710 | 0.620 |
Why?
|
| Combined Modality Therapy | 30 | 2020 | 8536 | 0.620 |
Why?
|
| Neoplasm, Residual | 6 | 2024 | 1014 | 0.610 |
Why?
|
| Substance Abuse, Intravenous | 6 | 2019 | 530 | 0.610 |
Why?
|
| Drug Synergism | 32 | 2018 | 1760 | 0.600 |
Why?
|
| Antibodies | 4 | 2023 | 2421 | 0.600 |
Why?
|
| Karyopherins | 4 | 2021 | 134 | 0.600 |
Why?
|
| Osteoclasts | 12 | 2018 | 713 | 0.590 |
Why?
|
| Stromal Cells | 36 | 2015 | 1336 | 0.590 |
Why?
|
| HIV Infections | 27 | 2021 | 17569 | 0.590 |
Why?
|
| Prednisolone | 6 | 2019 | 326 | 0.580 |
Why?
|
| Anti-HIV Agents | 13 | 2021 | 4573 | 0.580 |
Why?
|
| Practice Guidelines as Topic | 11 | 2021 | 7439 | 0.570 |
Why?
|
| Histone Deacetylases | 6 | 2018 | 717 | 0.570 |
Why?
|
| Chromosome Aberrations | 5 | 2020 | 1777 | 0.560 |
Why?
|
| Mice, SCID | 32 | 2017 | 2627 | 0.550 |
Why?
|
| Immunotherapy | 16 | 2024 | 4748 | 0.550 |
Why?
|
| Asthenia | 3 | 2016 | 16 | 0.550 |
Why?
|
| Enzyme Inhibitors | 23 | 2012 | 3726 | 0.540 |
Why?
|
| Hematologic Diseases | 6 | 2021 | 498 | 0.530 |
Why?
|
| Compassionate Use Trials | 1 | 2016 | 50 | 0.530 |
Why?
|
| Liver Diseases, Alcoholic | 3 | 2017 | 162 | 0.530 |
Why?
|
| Bone Marrow Cells | 33 | 2015 | 2415 | 0.520 |
Why?
|
| Hematologic Neoplasms | 11 | 2023 | 1907 | 0.510 |
Why?
|
| Immunosuppressive Agents | 15 | 2018 | 4210 | 0.510 |
Why?
|
| Patient Dropouts | 3 | 2017 | 411 | 0.510 |
Why?
|
| Clinical Trials, Phase I as Topic | 7 | 2021 | 329 | 0.510 |
Why?
|
| Xenograft Model Antitumor Assays | 33 | 2017 | 3609 | 0.500 |
Why?
|
| Tumor Microenvironment | 11 | 2022 | 3951 | 0.500 |
Why?
|
| Prednisone | 13 | 2017 | 1567 | 0.500 |
Why?
|
| Plasmacytoma | 5 | 2021 | 170 | 0.490 |
Why?
|
| Hepatitis, Alcoholic | 4 | 2019 | 110 | 0.480 |
Why?
|
| Interleukin-6 | 43 | 2021 | 3228 | 0.480 |
Why?
|
| Multicenter Studies as Topic | 9 | 2021 | 1736 | 0.480 |
Why?
|
| Cell Proliferation | 48 | 2021 | 10471 | 0.480 |
Why?
|
| Pyridones | 4 | 2021 | 819 | 0.470 |
Why?
|
| Antineoplastic Agents, Hormonal | 6 | 2020 | 1536 | 0.470 |
Why?
|
| Signal Transduction | 51 | 2021 | 23640 | 0.470 |
Why?
|
| HIV Integrase Inhibitors | 3 | 2021 | 165 | 0.460 |
Why?
|
| Time Factors | 44 | 2020 | 40210 | 0.450 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 4 | 2021 | 861 | 0.450 |
Why?
|
| Bone Density Conservation Agents | 6 | 2014 | 797 | 0.450 |
Why?
|
| Sirolimus | 7 | 2014 | 1539 | 0.440 |
Why?
|
| Immunoglobulin D | 1 | 2013 | 55 | 0.440 |
Why?
|
| Animals | 123 | 2024 | 169225 | 0.440 |
Why?
|
| Thromboembolism | 3 | 2017 | 1003 | 0.420 |
Why?
|
| Tuberculosis, Miliary | 1 | 2012 | 13 | 0.420 |
Why?
|
| Baclofen | 3 | 2018 | 120 | 0.410 |
Why?
|
| Drugs, Investigational | 1 | 2015 | 211 | 0.410 |
Why?
|
| Alcoholism | 3 | 2020 | 1980 | 0.410 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 2021 | 1801 | 0.410 |
Why?
|
| Drug Screening Assays, Antitumor | 11 | 2015 | 719 | 0.410 |
Why?
|
| Cell Survival | 34 | 2018 | 5772 | 0.410 |
Why?
|
| Drug Therapy, Combination | 13 | 2019 | 6314 | 0.410 |
Why?
|
| Myeloma Proteins | 4 | 2021 | 71 | 0.410 |
Why?
|
| Zidovudine | 1 | 2014 | 625 | 0.410 |
Why?
|
| B-Lymphocytes | 13 | 2023 | 4791 | 0.400 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2014 | 184 | 0.400 |
Why?
|
| Transplantation, Homologous | 8 | 2020 | 4838 | 0.400 |
Why?
|
| Nevirapine | 4 | 2014 | 273 | 0.390 |
Why?
|
| Pentoxifylline | 4 | 2016 | 53 | 0.390 |
Why?
|
| Pyrazoles | 10 | 2018 | 2028 | 0.390 |
Why?
|
| Clodronic Acid | 1 | 2011 | 60 | 0.390 |
Why?
|
| Jaw Diseases | 3 | 2009 | 91 | 0.380 |
Why?
|
| Adjuvants, Immunologic | 6 | 2003 | 998 | 0.380 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2024 | 2906 | 0.380 |
Why?
|
| Cell Membrane | 1 | 2021 | 3657 | 0.380 |
Why?
|
| Fatigue | 8 | 2022 | 1557 | 0.370 |
Why?
|
| Vascular Diseases | 5 | 2021 | 1162 | 0.370 |
Why?
|
| Venous Thromboembolism | 3 | 2022 | 1883 | 0.370 |
Why?
|
| Glucocorticoids | 10 | 2016 | 2166 | 0.370 |
Why?
|
| Renal Dialysis | 2 | 2020 | 1791 | 0.370 |
Why?
|
| Vincristine | 3 | 2010 | 1040 | 0.370 |
Why?
|
| Cysteine Proteinase Inhibitors | 6 | 2012 | 185 | 0.370 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 1666 | 0.360 |
Why?
|
| Oncogenes | 2 | 2016 | 1232 | 0.360 |
Why?
|
| Models, Psychological | 1 | 2015 | 825 | 0.360 |
Why?
|
| Dendritic Cells | 11 | 2017 | 2746 | 0.360 |
Why?
|
| Osteolysis | 2 | 2012 | 274 | 0.360 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2011 | 128 | 0.350 |
Why?
|
| Plasma Cells | 7 | 2018 | 599 | 0.350 |
Why?
|
| Young Adult | 36 | 2021 | 60050 | 0.350 |
Why?
|
| Pyrimidines | 9 | 2018 | 3046 | 0.350 |
Why?
|
| Blood Coagulation Factors | 1 | 2012 | 371 | 0.350 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 10 | 2015 | 1405 | 0.350 |
Why?
|
| Data Interpretation, Statistical | 2 | 2018 | 2708 | 0.350 |
Why?
|
| Enterococcus faecalis | 1 | 2011 | 244 | 0.350 |
Why?
|
| Piperidones | 2 | 2024 | 37 | 0.340 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 5 | 2005 | 263 | 0.330 |
Why?
|
| Intestinal Perforation | 1 | 2011 | 254 | 0.330 |
Why?
|
| Research Design | 4 | 2021 | 6212 | 0.330 |
Why?
|
| Standard of Care | 2 | 2011 | 569 | 0.330 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2017 | 1804 | 0.330 |
Why?
|
| Bone Diseases | 5 | 2016 | 416 | 0.330 |
Why?
|
| Adolescent | 42 | 2022 | 89154 | 0.330 |
Why?
|
| Graft vs Host Disease | 7 | 2021 | 3049 | 0.330 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2014 | 1354 | 0.320 |
Why?
|
| Acute Kidney Injury | 3 | 2020 | 1946 | 0.320 |
Why?
|
| Forecasting | 4 | 2016 | 2945 | 0.320 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2011 | 342 | 0.320 |
Why?
|
| Bone Marrow Neoplasms | 2 | 2006 | 101 | 0.310 |
Why?
|
| Proto-Oncogene Proteins | 15 | 2020 | 4525 | 0.310 |
Why?
|
| Incidence | 18 | 2020 | 21533 | 0.310 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 2726 | 0.310 |
Why?
|
| Nausea | 4 | 2017 | 682 | 0.310 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 3 | 2018 | 40 | 0.300 |
Why?
|
| Proton Pump Inhibitors | 3 | 2022 | 551 | 0.300 |
Why?
|
| Opiate Substitution Treatment | 4 | 2018 | 452 | 0.300 |
Why?
|
| Drug Discovery | 4 | 2021 | 1068 | 0.300 |
Why?
|
| Hematinics | 1 | 2011 | 282 | 0.300 |
Why?
|
| Disease Management | 7 | 2021 | 2533 | 0.290 |
Why?
|
| Treatment Failure | 6 | 2022 | 2660 | 0.290 |
Why?
|
| Amyloidosis | 3 | 2014 | 878 | 0.290 |
Why?
|
| MAP Kinase Signaling System | 7 | 2017 | 1492 | 0.290 |
Why?
|
| Kidney Diseases | 3 | 2021 | 2101 | 0.290 |
Why?
|
| Immunoglobulins | 5 | 2017 | 854 | 0.290 |
Why?
|
| Cysteine Endopeptidases | 13 | 2012 | 542 | 0.290 |
Why?
|
| Caspases | 17 | 2016 | 882 | 0.290 |
Why?
|
| Leukocytes, Mononuclear | 7 | 2021 | 1854 | 0.280 |
Why?
|
| Anti-Ulcer Agents | 1 | 2008 | 112 | 0.280 |
Why?
|
| Apoptosis Regulatory Proteins | 7 | 2024 | 1150 | 0.280 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 5 | 2018 | 306 | 0.280 |
Why?
|
| Cyclophosphamide | 10 | 2021 | 2227 | 0.280 |
Why?
|
| Aminoglycosides | 3 | 2016 | 161 | 0.280 |
Why?
|
| Immunoglobulin E | 1 | 2013 | 1497 | 0.280 |
Why?
|
| Cancer Vaccines | 5 | 2018 | 1041 | 0.270 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 5 | 2024 | 694 | 0.270 |
Why?
|
| Cyclohexanes | 2 | 2017 | 151 | 0.270 |
Why?
|
| Naloxone | 3 | 2015 | 372 | 0.270 |
Why?
|
| Ubiquitin | 7 | 2022 | 843 | 0.270 |
Why?
|
| Coculture Techniques | 14 | 2016 | 1340 | 0.270 |
Why?
|
| Neoplasms | 21 | 2018 | 22369 | 0.270 |
Why?
|
| Retrospective Studies | 37 | 2024 | 81748 | 0.270 |
Why?
|
| Arsenicals | 4 | 2017 | 117 | 0.260 |
Why?
|
| Liver Diseases | 2 | 2012 | 1305 | 0.260 |
Why?
|
| Syndecan-1 | 6 | 2015 | 163 | 0.260 |
Why?
|
| Piperidines | 6 | 2018 | 1667 | 0.260 |
Why?
|
| Bilirubin | 5 | 2019 | 438 | 0.260 |
Why?
|
| Anemia | 3 | 2014 | 1514 | 0.260 |
Why?
|
| Cell Adhesion | 23 | 2016 | 3096 | 0.260 |
Why?
|
| Mice | 71 | 2024 | 82024 | 0.260 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 575 | 0.260 |
Why?
|
| Herpes Zoster | 1 | 2008 | 252 | 0.260 |
Why?
|
| DNA Damage | 5 | 2016 | 2470 | 0.250 |
Why?
|
| Prospective Studies | 23 | 2022 | 54921 | 0.250 |
Why?
|
| Risk | 9 | 2021 | 9609 | 0.250 |
Why?
|
| Killer Cells, Natural | 8 | 2024 | 2211 | 0.250 |
Why?
|
| Leukocyte Count | 7 | 2019 | 1609 | 0.250 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 2 | 2017 | 168 | 0.250 |
Why?
|
| Child, Preschool | 18 | 2020 | 42665 | 0.250 |
Why?
|
| Seat Belts | 2 | 1997 | 60 | 0.250 |
Why?
|
| Receptors, Interleukin-17 | 2 | 2024 | 82 | 0.250 |
Why?
|
| Neoplastic Stem Cells | 4 | 2019 | 1351 | 0.250 |
Why?
|
| Risk Factors | 36 | 2024 | 74938 | 0.240 |
Why?
|
| Stress, Physiological | 1 | 2012 | 1409 | 0.240 |
Why?
|
| Alcohol Drinking | 3 | 2017 | 4045 | 0.240 |
Why?
|
| Abdominal Pain | 1 | 2011 | 1070 | 0.240 |
Why?
|
| Azepines | 3 | 2020 | 329 | 0.240 |
Why?
|
| Cell Division | 26 | 2013 | 4473 | 0.240 |
Why?
|
| Oxides | 4 | 2017 | 403 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor A | 20 | 2008 | 3514 | 0.240 |
Why?
|
| Tumor Necrosis Factor-alpha | 14 | 2006 | 4351 | 0.240 |
Why?
|
| Parietal Bone | 1 | 2004 | 49 | 0.240 |
Why?
|
| Child | 22 | 2023 | 80905 | 0.240 |
Why?
|
| Platelet Count | 3 | 2017 | 786 | 0.240 |
Why?
|
| Infusions, Intravenous | 6 | 2020 | 2227 | 0.240 |
Why?
|
| Glucuronidase | 2 | 2021 | 205 | 0.230 |
Why?
|
| Xenopus | 2 | 2006 | 711 | 0.230 |
Why?
|
| Phthalimides | 1 | 2024 | 34 | 0.230 |
Why?
|
| Bone Remodeling | 4 | 2014 | 582 | 0.230 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2021 | 5694 | 0.230 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2021 | 2884 | 0.230 |
Why?
|
| Insulin-Like Growth Factor I | 18 | 2009 | 1942 | 0.230 |
Why?
|
| Gastroesophageal Reflux | 2 | 2011 | 836 | 0.230 |
Why?
|
| Heterocyclic Compounds | 2 | 2019 | 245 | 0.230 |
Why?
|
| Blood Proteins | 4 | 2021 | 1191 | 0.230 |
Why?
|
| Gene Expression Profiling | 19 | 2020 | 9536 | 0.220 |
Why?
|
| Barrett Esophagus | 1 | 2008 | 495 | 0.220 |
Why?
|
| Fever | 1 | 2011 | 1613 | 0.220 |
Why?
|
| Pandemics | 2 | 2021 | 8750 | 0.220 |
Why?
|
| Skull Neoplasms | 1 | 2004 | 173 | 0.220 |
Why?
|
| Infant | 18 | 2020 | 36533 | 0.220 |
Why?
|
| Organic Chemicals | 1 | 2004 | 211 | 0.220 |
Why?
|
| Age Factors | 12 | 2021 | 18405 | 0.220 |
Why?
|
| Cell Cycle | 18 | 2017 | 2932 | 0.220 |
Why?
|
| Biological Therapy | 1 | 2005 | 140 | 0.220 |
Why?
|
| Consensus | 6 | 2022 | 3210 | 0.220 |
Why?
|
| Cytogenetic Analysis | 3 | 2021 | 270 | 0.210 |
Why?
|
| Gastrointestinal Diseases | 3 | 2021 | 1207 | 0.210 |
Why?
|
| Bone Neoplasms | 5 | 2021 | 2564 | 0.210 |
Why?
|
| Down-Regulation | 15 | 2015 | 2936 | 0.210 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 7 | 2012 | 440 | 0.210 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2024 | 1074 | 0.210 |
Why?
|
| Periodicals as Topic | 2 | 2011 | 1465 | 0.210 |
Why?
|
| Severity of Illness Index | 13 | 2021 | 15944 | 0.210 |
Why?
|
| Lymphocytes | 8 | 2019 | 2614 | 0.210 |
Why?
|
| Liver Neoplasms | 3 | 2016 | 4362 | 0.200 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 2 | 2013 | 85 | 0.200 |
Why?
|
| United States | 25 | 2024 | 73033 | 0.200 |
Why?
|
| Breast Feeding | 5 | 2014 | 1363 | 0.200 |
Why?
|
| Morpholines | 2 | 2024 | 584 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2020 | 998 | 0.200 |
Why?
|
| Antigens, CD | 7 | 2021 | 4035 | 0.200 |
Why?
|
| Anti-Retroviral Agents | 3 | 2019 | 1789 | 0.200 |
Why?
|
| Viral Load | 5 | 2019 | 3396 | 0.200 |
Why?
|
| Poly(ADP-ribose) Polymerases | 10 | 2015 | 428 | 0.200 |
Why?
|
| Cytotoxicity, Immunologic | 7 | 2019 | 1353 | 0.190 |
Why?
|
| Ubiquitin Thiolesterase | 3 | 2016 | 456 | 0.190 |
Why?
|
| Proportional Hazards Models | 9 | 2018 | 12536 | 0.190 |
Why?
|
| Models, Biological | 11 | 2016 | 9493 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 3 | 2020 | 2903 | 0.190 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2009 | 225 | 0.190 |
Why?
|
| Sequence Analysis, DNA | 11 | 2018 | 4785 | 0.190 |
Why?
|
| Buprenorphine | 3 | 2015 | 667 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2017 | 3553 | 0.190 |
Why?
|
| Adenine | 3 | 2018 | 995 | 0.190 |
Why?
|
| Drug Resistance, Viral | 2 | 2019 | 869 | 0.190 |
Why?
|
| Phosphorylation | 24 | 2016 | 8314 | 0.190 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2019 | 1903 | 0.190 |
Why?
|
| Infant, Newborn | 12 | 2020 | 26418 | 0.190 |
Why?
|
| Drug Administration Routes | 1 | 2021 | 152 | 0.180 |
Why?
|
| Chemoprevention | 2 | 2014 | 327 | 0.180 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2021 | 24 | 0.180 |
Why?
|
| South Africa | 5 | 2020 | 1873 | 0.180 |
Why?
|
| Epigenesis, Genetic | 7 | 2024 | 3834 | 0.180 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2021 | 85 | 0.180 |
Why?
|
| Kidney Transplantation | 2 | 2013 | 4271 | 0.180 |
Why?
|
| I-kappa B Kinase | 5 | 2009 | 250 | 0.180 |
Why?
|
| Blotting, Western | 14 | 2017 | 5023 | 0.180 |
Why?
|
| Canada | 5 | 2020 | 2130 | 0.180 |
Why?
|
| Peptides | 6 | 2018 | 4354 | 0.180 |
Why?
|
| Viral Tropism | 1 | 2021 | 102 | 0.170 |
Why?
|
| Benzylamines | 2 | 2019 | 251 | 0.170 |
Why?
|
| Frail Elderly | 3 | 2021 | 781 | 0.170 |
Why?
|
| Benzylidene Compounds | 1 | 2020 | 25 | 0.170 |
Why?
|
| beta 2-Microglobulin | 3 | 2012 | 330 | 0.170 |
Why?
|
| Glucans | 1 | 2020 | 71 | 0.170 |
Why?
|
| MicroRNAs | 4 | 2023 | 3804 | 0.170 |
Why?
|
| Europe | 4 | 2020 | 3438 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinases | 8 | 2007 | 1244 | 0.170 |
Why?
|
| Needle Sharing | 1 | 2019 | 22 | 0.170 |
Why?
|
| Schwann Cells | 2 | 2011 | 195 | 0.170 |
Why?
|
| HIV-1 | 7 | 2020 | 6960 | 0.170 |
Why?
|
| bcl-X Protein | 2 | 2015 | 412 | 0.170 |
Why?
|
| Trisomy | 1 | 2021 | 260 | 0.170 |
Why?
|
| Safety | 3 | 2014 | 1159 | 0.170 |
Why?
|
| Organ Specificity | 3 | 2021 | 1969 | 0.170 |
Why?
|
| Enzyme Activation | 14 | 2016 | 3587 | 0.170 |
Why?
|
| Mitochondria | 8 | 2020 | 3681 | 0.170 |
Why?
|
| Fractures, Comminuted | 1 | 2000 | 58 | 0.170 |
Why?
|
| Electrons | 2 | 2015 | 264 | 0.170 |
Why?
|
| B-Cell Activating Factor | 3 | 2016 | 116 | 0.160 |
Why?
|
| Quinazolinones | 2 | 2012 | 219 | 0.160 |
Why?
|
| Median Nerve | 1 | 2000 | 133 | 0.160 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2021 | 124 | 0.160 |
Why?
|
| Positron-Emission Tomography | 6 | 2017 | 6668 | 0.160 |
Why?
|
| Luminescent Measurements | 2 | 2012 | 342 | 0.160 |
Why?
|
| Cell Movement | 13 | 2016 | 5209 | 0.160 |
Why?
|
| Nanotubes | 1 | 2020 | 83 | 0.160 |
Why?
|
| Spain | 3 | 2020 | 484 | 0.160 |
Why?
|
| Valine | 1 | 2021 | 410 | 0.160 |
Why?
|
| Cytokines | 16 | 2014 | 7453 | 0.160 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2014 | 296 | 0.160 |
Why?
|
| Fibrinolysis | 2 | 2011 | 331 | 0.160 |
Why?
|
| Contraceptive Agents, Female | 1 | 2020 | 123 | 0.160 |
Why?
|
| RNA, Neoplasm | 2 | 2021 | 748 | 0.160 |
Why?
|
| Hypotension, Orthostatic | 1 | 2022 | 258 | 0.160 |
Why?
|
| beta-Glucans | 1 | 2020 | 129 | 0.160 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2021 | 304 | 0.160 |
Why?
|
| Testicular Neoplasms | 2 | 2018 | 806 | 0.160 |
Why?
|
| Immunoglobulin G | 3 | 2017 | 4565 | 0.160 |
Why?
|
| Phosphoramide Mustards | 1 | 2018 | 18 | 0.160 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2018 | 2596 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2021 | 640 | 0.160 |
Why?
|
| Depsipeptides | 2 | 2010 | 95 | 0.160 |
Why?
|
| Subtilisins | 1 | 1999 | 80 | 0.160 |
Why?
|
| NAD | 2 | 2013 | 618 | 0.160 |
Why?
|
| Cohort Studies | 19 | 2020 | 41753 | 0.150 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2018 | 498 | 0.150 |
Why?
|
| Nerve Growth Factors | 2 | 1999 | 564 | 0.150 |
Why?
|
| Genome, Bacterial | 4 | 2008 | 796 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 6 | 2012 | 474 | 0.150 |
Why?
|
| DNA-Binding Proteins | 14 | 2020 | 9614 | 0.150 |
Why?
|
| Galectins | 1 | 2021 | 295 | 0.150 |
Why?
|
| Cell Communication | 8 | 2009 | 1660 | 0.150 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 1 | 2018 | 55 | 0.150 |
Why?
|
| Immunoglobulin M | 5 | 2017 | 1527 | 0.150 |
Why?
|
| Drug Evaluation | 3 | 2013 | 642 | 0.150 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2012 | 617 | 0.150 |
Why?
|
| T-Lymphocytes | 10 | 2015 | 10264 | 0.150 |
Why?
|
| Immune Tolerance | 2 | 2018 | 2324 | 0.150 |
Why?
|
| DNA, Bacterial | 2 | 2016 | 1478 | 0.150 |
Why?
|
| Catheter Ablation | 1 | 2011 | 2787 | 0.150 |
Why?
|
| Expressed Sequence Tags | 3 | 2010 | 251 | 0.150 |
Why?
|
| Thrombophilia | 1 | 2021 | 308 | 0.150 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2010 | 394 | 0.150 |
Why?
|
| Humerus | 1 | 2000 | 273 | 0.150 |
Why?
|
| Drug Users | 1 | 2019 | 134 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 1883 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 13 | 3 | 2009 | 192 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 11 | 2013 | 2630 | 0.150 |
Why?
|
| Benzamides | 3 | 2015 | 1377 | 0.140 |
Why?
|
| Intention to Treat Analysis | 4 | 2021 | 416 | 0.140 |
Why?
|
| Multivariate Analysis | 9 | 2014 | 12075 | 0.140 |
Why?
|
| Nitroimidazoles | 1 | 2018 | 118 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 19 | 3 | 2004 | 350 | 0.140 |
Why?
|
| Lymphoma, Follicular | 1 | 2002 | 460 | 0.140 |
Why?
|
| GTP Phosphohydrolases | 3 | 2020 | 525 | 0.140 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2017 | 2428 | 0.140 |
Why?
|
| Infant Equipment | 1 | 1997 | 23 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 5 | 2012 | 478 | 0.140 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2017 | 82 | 0.140 |
Why?
|
| AIDS Vaccines | 2 | 2014 | 900 | 0.140 |
Why?
|
| Terphenyl Compounds | 1 | 2016 | 7 | 0.140 |
Why?
|
| Phosphotransferases | 1 | 2018 | 302 | 0.140 |
Why?
|
| Blood Chemical Analysis | 1 | 2019 | 435 | 0.140 |
Why?
|
| Odds Ratio | 4 | 2020 | 9667 | 0.140 |
Why?
|
| Flow Cytometry | 16 | 2015 | 5904 | 0.140 |
Why?
|
| Immunoconjugates | 2 | 2018 | 975 | 0.140 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2017 | 144 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 3669 | 0.140 |
Why?
|
| Pain | 3 | 2021 | 5100 | 0.140 |
Why?
|
| Interleukin-17 | 2 | 2015 | 925 | 0.140 |
Why?
|
| Pneumonia | 2 | 2021 | 2164 | 0.140 |
Why?
|
| Respiration Disorders | 1 | 2020 | 364 | 0.140 |
Why?
|
| Premedication | 2 | 2007 | 245 | 0.140 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2011 | 661 | 0.140 |
Why?
|
| Sulfides | 1 | 2017 | 171 | 0.140 |
Why?
|
| Cardiovascular Diseases | 4 | 2017 | 15662 | 0.130 |
Why?
|
| Medical Informatics Applications | 1 | 2018 | 180 | 0.130 |
Why?
|
| Immunoglobulin lambda-Chains | 2 | 2014 | 84 | 0.130 |
Why?
|
| Pemphigus | 1 | 2017 | 107 | 0.130 |
Why?
|
| Amides | 3 | 2015 | 451 | 0.130 |
Why?
|
| Endothelial Growth Factors | 7 | 2003 | 671 | 0.130 |
Why?
|
| Nitro Compounds | 1 | 2016 | 74 | 0.130 |
Why?
|
| Early Diagnosis | 4 | 2019 | 1193 | 0.130 |
Why?
|
| Biomedical Research | 2 | 2010 | 3464 | 0.130 |
Why?
|
| Heparin | 2 | 2021 | 1636 | 0.130 |
Why?
|
| Exanthema | 3 | 2017 | 502 | 0.130 |
Why?
|
| Cell Death | 8 | 2017 | 1679 | 0.130 |
Why?
|
| Genomics | 7 | 2021 | 5925 | 0.130 |
Why?
|
| Monocytes | 2 | 2016 | 2604 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 9 | 2013 | 3798 | 0.130 |
Why?
|
| Carbon Radioisotopes | 1 | 2017 | 567 | 0.130 |
Why?
|
| Mutation | 14 | 2021 | 30214 | 0.130 |
Why?
|
| Lymphokines | 7 | 2003 | 924 | 0.130 |
Why?
|
| Japan | 1 | 2020 | 1418 | 0.130 |
Why?
|
| Ubiquitins | 2 | 2012 | 366 | 0.130 |
Why?
|
| Blood Cell Count | 1 | 2016 | 406 | 0.130 |
Why?
|
| France | 2 | 2015 | 497 | 0.120 |
Why?
|
| Growth Substances | 3 | 2006 | 759 | 0.120 |
Why?
|
| Patient Selection | 3 | 2020 | 4258 | 0.120 |
Why?
|
| Osteogenesis | 2 | 2021 | 1288 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2023 | 3626 | 0.120 |
Why?
|
| Procollagen | 1 | 2016 | 189 | 0.120 |
Why?
|
| Benzoxazoles | 1 | 2016 | 92 | 0.120 |
Why?
|
| Drug Delivery Systems | 6 | 2017 | 2230 | 0.120 |
Why?
|
| Collagen Type I | 2 | 2016 | 618 | 0.120 |
Why?
|
| Jaw | 1 | 2015 | 95 | 0.120 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2017 | 2889 | 0.120 |
Why?
|
| Biopsy | 8 | 2019 | 6786 | 0.120 |
Why?
|
| Genome, Archaeal | 2 | 2006 | 21 | 0.120 |
Why?
|
| Sciatic Nerve | 1 | 1999 | 627 | 0.120 |
Why?
|
| Sepsis | 3 | 2022 | 2608 | 0.120 |
Why?
|
| Phosphodiesterase Inhibitors | 3 | 2015 | 213 | 0.120 |
Why?
|
| Benzimidazoles | 3 | 2015 | 863 | 0.120 |
Why?
|
| Immunoblotting | 8 | 2015 | 1647 | 0.120 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2014 | 705 | 0.120 |
Why?
|
| Injections, Intramuscular | 3 | 2021 | 554 | 0.120 |
Why?
|
| Muscle, Smooth | 1 | 1999 | 931 | 0.120 |
Why?
|
| Placebos | 5 | 2020 | 1667 | 0.120 |
Why?
|
| Medical Oncology | 3 | 2012 | 2341 | 0.120 |
Why?
|
| Azetidines | 1 | 2016 | 152 | 0.120 |
Why?
|
| Colorectal Neoplasms | 2 | 2012 | 6973 | 0.120 |
Why?
|
| Antirheumatic Agents | 1 | 2004 | 1381 | 0.120 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2015 | 99 | 0.120 |
Why?
|
| Diarrhea | 2 | 2016 | 1320 | 0.120 |
Why?
|
| Lymphocyte Activation | 11 | 2021 | 5505 | 0.120 |
Why?
|
| Acyltransferases | 3 | 2007 | 306 | 0.120 |
Why?
|
| Proteins | 9 | 2021 | 6009 | 0.120 |
Why?
|
| Receptors, IgG | 1 | 2018 | 564 | 0.120 |
Why?
|
| United States Department of Veterans Affairs | 4 | 2019 | 937 | 0.120 |
Why?
|
| Malawi | 3 | 2020 | 312 | 0.120 |
Why?
|
| Liver Cirrhosis | 3 | 2016 | 1960 | 0.120 |
Why?
|
| Hypersensitivity, Delayed | 2 | 2014 | 491 | 0.120 |
Why?
|
| Geography | 1 | 2016 | 652 | 0.120 |
Why?
|
| Interferon Regulatory Factors | 1 | 2016 | 271 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 5 | 2017 | 1605 | 0.110 |
Why?
|
| Confidence Intervals | 1 | 2020 | 2923 | 0.110 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 1995 | 97 | 0.110 |
Why?
|
| Fluorine Radioisotopes | 1 | 2017 | 425 | 0.110 |
Why?
|
| Obstetric Labor, Premature | 1 | 1996 | 268 | 0.110 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2018 | 827 | 0.110 |
Why?
|
| Acrylamides | 2 | 2013 | 261 | 0.110 |
Why?
|
| Matched-Pair Analysis | 1 | 2014 | 285 | 0.110 |
Why?
|
| Brazil | 4 | 2020 | 1250 | 0.110 |
Why?
|
| Rectum | 1 | 2019 | 900 | 0.110 |
Why?
|
| Drug Eruptions | 1 | 2017 | 335 | 0.110 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2022 | 279 | 0.110 |
Why?
|
| HIV Antigens | 1 | 2014 | 328 | 0.110 |
Why?
|
| Drug Resistance, Multiple | 3 | 2005 | 255 | 0.110 |
Why?
|
| Hemorrhage | 3 | 2020 | 3467 | 0.110 |
Why?
|
| Carcinoma, Small Cell | 3 | 2002 | 419 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2017 | 1621 | 0.110 |
Why?
|
| Immunoglobulin A | 1 | 2017 | 992 | 0.110 |
Why?
|
| Vomiting | 1 | 2017 | 655 | 0.110 |
Why?
|
| Nitrogen | 1 | 2015 | 345 | 0.110 |
Why?
|
| Nephritis, Interstitial | 1 | 1995 | 157 | 0.110 |
Why?
|
| Immunotoxins | 1 | 2014 | 175 | 0.110 |
Why?
|
| Acute Lung Injury | 1 | 2017 | 377 | 0.110 |
Why?
|
| Telomerase | 3 | 2003 | 751 | 0.110 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2013 | 37 | 0.110 |
Why?
|
| Growth Inhibitors | 3 | 2004 | 375 | 0.110 |
Why?
|
| Bone Marrow Purging | 2 | 2004 | 108 | 0.110 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2015 | 260 | 0.110 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2014 | 238 | 0.110 |
Why?
|
| Germany | 1 | 2015 | 882 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2014 | 1642 | 0.110 |
Why?
|
| Referral and Consultation | 3 | 2019 | 3619 | 0.110 |
Why?
|
| I-kappa B Proteins | 5 | 2009 | 210 | 0.110 |
Why?
|
| RNA, Small Interfering | 9 | 2015 | 3428 | 0.110 |
Why?
|
| Mice, Inbred NOD | 4 | 2012 | 1837 | 0.100 |
Why?
|
| Gene Expression | 6 | 2020 | 7597 | 0.100 |
Why?
|
| Chromosome Deletion | 3 | 2006 | 1384 | 0.100 |
Why?
|
| Genes | 4 | 2004 | 1824 | 0.100 |
Why?
|
| Liver | 5 | 2012 | 7575 | 0.100 |
Why?
|
| Genes, ras | 1 | 2015 | 657 | 0.100 |
Why?
|
| Terminal Care | 2 | 2018 | 1770 | 0.100 |
Why?
|
| Estradiol | 3 | 2007 | 1951 | 0.100 |
Why?
|
| Glomerulonephritis | 1 | 1995 | 333 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2017 | 2054 | 0.100 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 507 | 0.100 |
Why?
|
| Sirtuins | 1 | 2015 | 322 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2012 | 361 | 0.100 |
Why?
|
| Drug Design | 4 | 2017 | 1045 | 0.100 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2014 | 197 | 0.100 |
Why?
|
| Cryoglobulins | 1 | 2012 | 58 | 0.100 |
Why?
|
| Transcription, Genetic | 5 | 2021 | 7613 | 0.100 |
Why?
|
| Neutrophils | 2 | 2019 | 3786 | 0.100 |
Why?
|
| Palliative Care | 4 | 2021 | 3642 | 0.100 |
Why?
|
| Cyclohexanones | 1 | 2012 | 30 | 0.100 |
Why?
|
| Transplantation, Heterologous | 9 | 2015 | 2392 | 0.100 |
Why?
|
| Plant Growth Regulators | 1 | 2012 | 51 | 0.100 |
Why?
|
| Plasma Exchange | 1 | 2013 | 160 | 0.100 |
Why?
|
| DNA Copy Number Variations | 2 | 2019 | 2048 | 0.100 |
Why?
|
| Piperazines | 4 | 2011 | 2552 | 0.100 |
Why?
|
| Oxylipins | 1 | 2012 | 54 | 0.100 |
Why?
|
| Cyclopentanes | 1 | 2012 | 87 | 0.100 |
Why?
|
| G1 Phase | 2 | 2012 | 403 | 0.100 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2020 | 2442 | 0.100 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2012 | 1059 | 0.100 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 1065 | 0.100 |
Why?
|
| Gastroenterology | 1 | 2019 | 593 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2011 | 681 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2020 | 2953 | 0.100 |
Why?
|
| Delivery of Health Care | 4 | 2019 | 5366 | 0.100 |
Why?
|
| Leukopenia | 1 | 2012 | 212 | 0.100 |
Why?
|
| Gene Duplication | 4 | 2006 | 315 | 0.100 |
Why?
|
| Purines | 3 | 2010 | 615 | 0.100 |
Why?
|
| Cryoglobulinemia | 1 | 2012 | 84 | 0.100 |
Why?
|
| Epoxy Compounds | 1 | 2012 | 137 | 0.100 |
Why?
|
| Aspirin | 2 | 2022 | 3135 | 0.100 |
Why?
|
| Cluster Analysis | 3 | 2015 | 2731 | 0.100 |
Why?
|
| Duodenitis | 1 | 2011 | 20 | 0.100 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2008 | 1196 | 0.100 |
Why?
|
| Creatinine | 2 | 2016 | 1918 | 0.100 |
Why?
|
| Health Resources | 1 | 2018 | 950 | 0.100 |
Why?
|
| Alkaline Phosphatase | 4 | 2011 | 863 | 0.100 |
Why?
|
| Fatal Outcome | 3 | 2015 | 1836 | 0.100 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2012 | 85 | 0.100 |
Why?
|
| ras Proteins | 2 | 2014 | 1054 | 0.100 |
Why?
|
| Breast Neoplasms | 15 | 2009 | 21209 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 1697 | 0.090 |
Why?
|
| Alkylating Agents | 2 | 2023 | 132 | 0.090 |
Why?
|
| High-Throughput Screening Assays | 3 | 2012 | 942 | 0.090 |
Why?
|
| Histocytochemistry | 1 | 2012 | 699 | 0.090 |
Why?
|
| Thiocyanates | 1 | 2011 | 70 | 0.090 |
Why?
|
| Up-Regulation | 12 | 2013 | 4146 | 0.090 |
Why?
|
| Demography | 1 | 2016 | 1641 | 0.090 |
Why?
|
| Gene Library | 2 | 2006 | 1065 | 0.090 |
Why?
|
| Isothiocyanates | 1 | 2011 | 48 | 0.090 |
Why?
|
| Enterochromaffin-like Cells | 1 | 2011 | 4 | 0.090 |
Why?
|
| p21-Activated Kinases | 1 | 2012 | 127 | 0.090 |
Why?
|
| Cyclobutanes | 1 | 2011 | 57 | 0.090 |
Why?
|
| Chromosome Mapping | 5 | 2008 | 4618 | 0.090 |
Why?
|
| Antigens, Neoplasm | 4 | 2018 | 1997 | 0.090 |
Why?
|
| Pteridines | 1 | 2011 | 47 | 0.090 |
Why?
|
| Steroids | 1 | 2016 | 938 | 0.090 |
Why?
|
| Caspase 9 | 6 | 2011 | 184 | 0.090 |
Why?
|
| Accidents, Traffic | 1 | 1997 | 818 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2011 | 71 | 0.090 |
Why?
|
| Disease Transmission, Infectious | 1 | 2017 | 560 | 0.090 |
Why?
|
| Geriatric Assessment | 2 | 2018 | 1422 | 0.090 |
Why?
|
| Transcription Factors | 10 | 2014 | 12165 | 0.090 |
Why?
|
| Membrane Proteins | 6 | 2021 | 7876 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2015 | 549 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 1240 | 0.090 |
Why?
|
| Hospice Care | 1 | 2018 | 678 | 0.090 |
Why?
|
| Medical Audit | 1 | 2012 | 454 | 0.090 |
Why?
|
| Cell Differentiation | 7 | 2016 | 11666 | 0.090 |
Why?
|
| Gastritis, Atrophic | 1 | 2011 | 31 | 0.090 |
Why?
|
| MAP Kinase Kinase 1 | 3 | 2010 | 330 | 0.090 |
Why?
|
| Fluorouracil | 3 | 2012 | 1653 | 0.090 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2015 | 412 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factors | 8 | 2006 | 748 | 0.090 |
Why?
|
| Acetates | 1 | 2012 | 317 | 0.090 |
Why?
|
| Caspase 3 | 6 | 2011 | 730 | 0.090 |
Why?
|
| Risk Assessment | 10 | 2023 | 24317 | 0.090 |
Why?
|
| MAP Kinase Kinase 2 | 2 | 2010 | 92 | 0.090 |
Why?
|
| Venous Thrombosis | 3 | 2011 | 1323 | 0.090 |
Why?
|
| Drug Combinations | 4 | 2017 | 2088 | 0.090 |
Why?
|
| Indonesia | 3 | 2019 | 131 | 0.090 |
Why?
|
| Minocycline | 1 | 2012 | 170 | 0.090 |
Why?
|
| Prevalence | 5 | 2016 | 15867 | 0.090 |
Why?
|
| Hypotension | 1 | 2017 | 888 | 0.090 |
Why?
|
| Activities of Daily Living | 2 | 2018 | 2429 | 0.090 |
Why?
|
| HIV | 2 | 2015 | 1597 | 0.090 |
Why?
|
| China | 5 | 2017 | 2395 | 0.090 |
Why?
|
| Hematopoiesis | 1 | 2020 | 2059 | 0.090 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 1032 | 0.090 |
Why?
|
| Labor, Obstetric | 1 | 2014 | 313 | 0.090 |
Why?
|
| HIV Antibodies | 2 | 2014 | 1341 | 0.090 |
Why?
|
| Body Image | 1 | 1996 | 646 | 0.090 |
Why?
|
| Cell Line | 12 | 2014 | 15597 | 0.090 |
Why?
|
| Burns | 2 | 2013 | 1899 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2014 | 2185 | 0.090 |
Why?
|
| Biphenyl Compounds | 2 | 2006 | 1026 | 0.090 |
Why?
|
| Postpartum Period | 2 | 2014 | 1198 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2015 | 4576 | 0.090 |
Why?
|
| Benchmarking | 1 | 2017 | 1057 | 0.090 |
Why?
|
| Cell Growth Processes | 5 | 2014 | 381 | 0.090 |
Why?
|
| International Classification of Diseases | 3 | 2019 | 936 | 0.090 |
Why?
|
| Endoribonucleases | 1 | 2012 | 231 | 0.090 |
Why?
|
| Adenosine A2 Receptor Agonists | 1 | 2010 | 31 | 0.090 |
Why?
|
| Catfishes | 1 | 2010 | 14 | 0.090 |
Why?
|
| Molecular Sequence Data | 15 | 2012 | 17617 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2016 | 1374 | 0.090 |
Why?
|
| Vaccination | 4 | 2019 | 3437 | 0.090 |
Why?
|
| Histones | 5 | 2024 | 2600 | 0.090 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2010 | 414 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2007 | 2272 | 0.090 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2012 | 215 | 0.090 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2011 | 174 | 0.080 |
Why?
|
| Genomic Instability | 1 | 2014 | 716 | 0.080 |
Why?
|
| Databases, Factual | 4 | 2020 | 8082 | 0.080 |
Why?
|
| Lysosomes | 1 | 2015 | 938 | 0.080 |
Why?
|
| Carbamates | 2 | 2012 | 192 | 0.080 |
Why?
|
| Bone Resorption | 5 | 2017 | 726 | 0.080 |
Why?
|
| Fibrinolysin | 1 | 2009 | 130 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 8 | 2014 | 1656 | 0.080 |
Why?
|
| Thiophenes | 2 | 2012 | 570 | 0.080 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2013 | 205 | 0.080 |
Why?
|
| Dental Fistula | 1 | 2009 | 12 | 0.080 |
Why?
|
| Narcotic Antagonists | 1 | 2014 | 591 | 0.080 |
Why?
|
| Tumor Burden | 5 | 2013 | 1904 | 0.080 |
Why?
|
| Tracheostomy | 1 | 2013 | 430 | 0.080 |
Why?
|
| Carcinoid Tumor | 1 | 2011 | 225 | 0.080 |
Why?
|
| Amidohydrolases | 2 | 2007 | 160 | 0.080 |
Why?
|
| Seawater | 2 | 2008 | 126 | 0.080 |
Why?
|
| Dyspnea | 1 | 2017 | 1352 | 0.080 |
Why?
|
| Pregnancy | 9 | 2015 | 30244 | 0.080 |
Why?
|
| Sensation Disorders | 1 | 2010 | 160 | 0.080 |
Why?
|
| Caspase 8 | 5 | 2011 | 198 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2004 | 3781 | 0.080 |
Why?
|
| Flavones | 1 | 2009 | 66 | 0.080 |
Why?
|
| Hemoglobins | 2 | 2007 | 1531 | 0.080 |
Why?
|
| Immunocompromised Host | 2 | 2012 | 863 | 0.080 |
Why?
|
| Drug Resistance | 4 | 2021 | 1598 | 0.080 |
Why?
|
| Algorithms | 5 | 2019 | 14163 | 0.080 |
Why?
|
| Thailand | 3 | 2015 | 288 | 0.080 |
Why?
|
| Intercellular Adhesion Molecule-1 | 4 | 2010 | 1134 | 0.080 |
Why?
|
| Antiviral Agents | 2 | 2019 | 3073 | 0.080 |
Why?
|
| Immunoglobulin Light Chains | 2 | 2008 | 289 | 0.080 |
Why?
|
| Drug Dosage Calculations | 1 | 2009 | 117 | 0.080 |
Why?
|
| Biomarkers, Pharmacological | 3 | 2019 | 161 | 0.080 |
Why?
|
| Desensitization, Immunologic | 1 | 2014 | 546 | 0.080 |
Why?
|
| Interleukin-2 | 4 | 2005 | 1895 | 0.080 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 3 | 2005 | 195 | 0.080 |
Why?
|
| Maytansine | 1 | 2009 | 88 | 0.080 |
Why?
|
| Water | 1 | 2015 | 1421 | 0.080 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2013 | 925 | 0.080 |
Why?
|
| Immunization, Passive | 3 | 2005 | 619 | 0.080 |
Why?
|
| Cerulenin | 1 | 2008 | 7 | 0.080 |
Why?
|
| Trichoderma | 1 | 2008 | 9 | 0.080 |
Why?
|
| Ukraine | 2 | 2019 | 151 | 0.080 |
Why?
|
| Drug Costs | 1 | 2016 | 1195 | 0.080 |
Why?
|
| Leukemia | 3 | 2008 | 1519 | 0.080 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2017 | 928 | 0.080 |
Why?
|
| Bone and Bones | 3 | 2017 | 2589 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 3740 | 0.080 |
Why?
|
| Uganda | 4 | 2014 | 1361 | 0.080 |
Why?
|
| Duodenum | 1 | 2011 | 495 | 0.080 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2008 | 590 | 0.080 |
Why?
|
| Chi-Square Distribution | 4 | 2008 | 3433 | 0.080 |
Why?
|
| Microspheres | 1 | 2011 | 788 | 0.080 |
Why?
|
| Brain Injuries | 1 | 2020 | 2057 | 0.080 |
Why?
|
| Eosinophilia | 1 | 2013 | 554 | 0.080 |
Why?
|
| Blood Component Removal | 1 | 2009 | 132 | 0.080 |
Why?
|
| Microcirculation | 1 | 2013 | 1281 | 0.080 |
Why?
|
| Naphthalenes | 2 | 2006 | 198 | 0.070 |
Why?
|
| Patient Compliance | 2 | 2017 | 2697 | 0.070 |
Why?
|
| Vietnam | 2 | 2019 | 415 | 0.070 |
Why?
|
| Neoplasm Transplantation | 5 | 2014 | 2014 | 0.070 |
Why?
|
| RNA, Messenger | 10 | 2015 | 12797 | 0.070 |
Why?
|
| Urinary Tract Infections | 1 | 2014 | 804 | 0.070 |
Why?
|
| Interferon-gamma | 5 | 2015 | 3159 | 0.070 |
Why?
|
| Gastric Acid | 1 | 2008 | 98 | 0.070 |
Why?
|
| Polyneuropathies | 1 | 2009 | 139 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2010 | 696 | 0.070 |
Why?
|
| Opioid-Related Disorders | 2 | 2014 | 2188 | 0.070 |
Why?
|
| Rats, Inbred F344 | 1 | 2009 | 826 | 0.070 |
Why?
|
| Receptors, Growth Factor | 2 | 2006 | 324 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2014 | 2473 | 0.070 |
Why?
|
| Myeloid Cells | 1 | 2013 | 839 | 0.070 |
Why?
|
| Tongue Diseases | 1 | 2008 | 69 | 0.070 |
Why?
|
| Niacinamide | 1 | 2010 | 418 | 0.070 |
Why?
|
| Root Nodules, Plant | 1 | 2007 | 11 | 0.070 |
Why?
|
| Hyperplasia | 1 | 2011 | 1151 | 0.070 |
Why?
|
| Plant Stems | 1 | 2007 | 19 | 0.070 |
Why?
|
| Bradyrhizobium | 1 | 2007 | 16 | 0.070 |
Why?
|
| Epitopes | 1 | 2014 | 2526 | 0.070 |
Why?
|
| Proteome | 3 | 2014 | 1890 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2012 | 887 | 0.070 |
Why?
|
| Microscopy | 1 | 2012 | 908 | 0.070 |
Why?
|
| RNA Splicing | 1 | 2012 | 905 | 0.070 |
Why?
|
| Oral Ulcer | 1 | 2008 | 95 | 0.070 |
Why?
|
| Mandibular Diseases | 1 | 2008 | 117 | 0.070 |
Why?
|
| Critical Pathways | 1 | 2011 | 476 | 0.070 |
Why?
|
| Cisplatin | 5 | 2021 | 1658 | 0.070 |
Why?
|
| RANK Ligand | 4 | 2012 | 321 | 0.070 |
Why?
|
| Risk Reduction Behavior | 2 | 2013 | 1119 | 0.070 |
Why?
|
| Gram-Positive Bacteria | 1 | 2008 | 179 | 0.070 |
Why?
|
| Clinical Protocols | 2 | 2013 | 1443 | 0.070 |
Why?
|
| Radiography | 3 | 2012 | 6981 | 0.070 |
Why?
|
| Physical Chromosome Mapping | 2 | 2004 | 183 | 0.070 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2007 | 141 | 0.070 |
Why?
|
| Streptococcaceae | 1 | 2006 | 4 | 0.070 |
Why?
|
| Gene Frequency | 2 | 2012 | 3623 | 0.070 |
Why?
|
| Tubulin Modulators | 1 | 2007 | 106 | 0.070 |
Why?
|
| Genome, Fungal | 1 | 2008 | 203 | 0.070 |
Why?
|
| Carboxylesterase | 1 | 2007 | 31 | 0.070 |
Why?
|
| Populus | 1 | 2006 | 10 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2021 | 635 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 4648 | 0.070 |
Why?
|
| Fabaceae | 1 | 2007 | 103 | 0.070 |
Why?
|
| DNA, Fungal | 1 | 2008 | 275 | 0.070 |
Why?
|
| ets-Domain Protein Elk-1 | 2 | 2017 | 39 | 0.070 |
Why?
|
| Medication Adherence | 2 | 2021 | 2187 | 0.070 |
Why?
|
| Sensitivity and Specificity | 8 | 2019 | 14718 | 0.070 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2006 | 37 | 0.070 |
Why?
|
| Transfection | 6 | 2015 | 5757 | 0.070 |
Why?
|
| Sex Factors | 3 | 2016 | 10629 | 0.070 |
Why?
|
| Cyclin D1 | 1 | 2009 | 453 | 0.070 |
Why?
|
| Injections | 2 | 2020 | 840 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2019 | 4055 | 0.070 |
Why?
|
| Homosexuality, Male | 3 | 2021 | 1344 | 0.070 |
Why?
|
| Fatty Liver | 1 | 2013 | 809 | 0.070 |
Why?
|
| Authorship | 1 | 2010 | 289 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2007 | 286 | 0.070 |
Why?
|
| Blood Coagulation | 1 | 2012 | 1163 | 0.070 |
Why?
|
| Crenarchaeota | 1 | 2006 | 2 | 0.070 |
Why?
|
| TCF Transcription Factors | 1 | 2007 | 138 | 0.070 |
Why?
|
| Cytotoxins | 1 | 2007 | 154 | 0.070 |
Why?
|
| Thrombomodulin | 2 | 2022 | 107 | 0.070 |
Why?
|
| Comorbidity | 2 | 2018 | 10590 | 0.070 |
Why?
|
| Cells, Cultured | 11 | 2018 | 19015 | 0.070 |
Why?
|
| Spleen | 1 | 2012 | 2295 | 0.070 |
Why?
|
| Genome, Plant | 1 | 2006 | 84 | 0.070 |
Why?
|
| Cell Cycle Proteins | 5 | 2011 | 3443 | 0.070 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2006 | 80 | 0.070 |
Why?
|
| Virus Activation | 1 | 2008 | 324 | 0.070 |
Why?
|
| Translocation, Genetic | 2 | 2014 | 1391 | 0.070 |
Why?
|
| Risk Management | 1 | 2010 | 558 | 0.070 |
Why?
|
| Statistics, Nonparametric | 3 | 2009 | 2854 | 0.070 |
Why?
|
| Lactams | 2 | 2017 | 159 | 0.070 |
Why?
|
| Delayed-Action Preparations | 2 | 2021 | 968 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2007 | 377 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 6 | 2016 | 7469 | 0.070 |
Why?
|
| Nitrophenols | 1 | 2006 | 169 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 3 | 2008 | 1369 | 0.060 |
Why?
|
| Exercise Therapy | 1 | 2013 | 939 | 0.060 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2004 | 304 | 0.060 |
Why?
|
| Crystallography, X-Ray | 4 | 2013 | 1951 | 0.060 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2016 | 1672 | 0.060 |
Why?
|
| Oncogene Protein v-akt | 1 | 2006 | 130 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2005 | 631 | 0.060 |
Why?
|
| Phosphoproteins | 2 | 2014 | 2450 | 0.060 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 26377 | 0.060 |
Why?
|
| Developmental Biology | 2 | 2006 | 79 | 0.060 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2020 | 433 | 0.060 |
Why?
|
| Halomonadaceae | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 1512 | 0.060 |
Why?
|
| Cell Nucleus | 4 | 2020 | 2881 | 0.060 |
Why?
|
| HIV Seronegativity | 2 | 2020 | 210 | 0.060 |
Why?
|
| Drug Monitoring | 3 | 2018 | 964 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2014 | 3814 | 0.060 |
Why?
|
| Rifabutin | 1 | 2005 | 59 | 0.060 |
Why?
|
| Peptide Fragments | 2 | 2016 | 5151 | 0.060 |
Why?
|
| Haptoglobins | 1 | 2007 | 165 | 0.060 |
Why?
|
| Erythrocytes | 1 | 2015 | 2418 | 0.060 |
Why?
|
| Scotland | 2 | 1997 | 142 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2005 | 5861 | 0.060 |
Why?
|
| Autophagy | 3 | 2024 | 1349 | 0.060 |
Why?
|
| RNA Polymerase II | 1 | 2010 | 549 | 0.060 |
Why?
|
| Osteoblasts | 4 | 2017 | 1145 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2012 | 958 | 0.060 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2009 | 489 | 0.060 |
Why?
|
| Macrophages | 2 | 1999 | 5798 | 0.060 |
Why?
|
| Propylene Glycols | 1 | 2005 | 91 | 0.060 |
Why?
|
| Salts | 1 | 2005 | 61 | 0.060 |
Why?
|
| Drug Hypersensitivity | 1 | 2014 | 903 | 0.060 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2023 | 582 | 0.060 |
Why?
|
| Glioblastoma | 1 | 2020 | 3463 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2012 | 16041 | 0.060 |
Why?
|
| Lactobacillus | 1 | 2006 | 212 | 0.060 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2007 | 131 | 0.060 |
Why?
|
| Drug Industry | 2 | 2010 | 791 | 0.060 |
Why?
|
| Kidney | 2 | 2019 | 7067 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2021 | 4854 | 0.060 |
Why?
|
| Ammonia | 1 | 2006 | 247 | 0.060 |
Why?
|
| Feasibility Studies | 4 | 2019 | 5314 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2007 | 319 | 0.060 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2012 | 1126 | 0.060 |
Why?
|
| Helicobacter pylori | 1 | 2008 | 380 | 0.060 |
Why?
|
| Schizophrenic Psychology | 1 | 2012 | 1649 | 0.060 |
Why?
|
| Conflict of Interest | 1 | 2010 | 556 | 0.060 |
Why?
|
| DNA, Neoplasm | 4 | 2020 | 1742 | 0.060 |
Why?
|
| Spiro Compounds | 1 | 2005 | 69 | 0.060 |
Why?
|
| Helicobacter Infections | 1 | 2008 | 390 | 0.060 |
Why?
|
| Carcinoma | 2 | 2009 | 2330 | 0.060 |
Why?
|
| Endpoint Determination | 1 | 2007 | 592 | 0.060 |
Why?
|
| Models, Molecular | 5 | 2015 | 5402 | 0.060 |
Why?
|
| Symbiosis | 1 | 2007 | 297 | 0.060 |
Why?
|
| Heart Diseases | 2 | 2017 | 2819 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 3116 | 0.060 |
Why?
|
| Lignans | 1 | 2005 | 83 | 0.060 |
Why?
|
| Bacteremia | 1 | 2011 | 986 | 0.060 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2010 | 977 | 0.060 |
Why?
|
| Control Groups | 2 | 2021 | 107 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2012 | 20757 | 0.060 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2004 | 108 | 0.060 |
Why?
|
| Caveolins | 1 | 2004 | 102 | 0.060 |
Why?
|
| Veterans | 2 | 2016 | 2669 | 0.060 |
Why?
|
| Immunophenotyping | 7 | 2009 | 1864 | 0.060 |
Why?
|
| Lactic Acid | 2 | 2006 | 1140 | 0.060 |
Why?
|
| Diclofenac | 1 | 2004 | 69 | 0.060 |
Why?
|
| Rats | 6 | 2012 | 23751 | 0.060 |
Why?
|
| Naproxen | 1 | 2004 | 101 | 0.060 |
Why?
|
| Celiac Disease | 1 | 2012 | 820 | 0.060 |
Why?
|
| Human Genome Project | 2 | 2004 | 202 | 0.060 |
Why?
|
| DNA, Complementary | 2 | 2010 | 1989 | 0.060 |
Why?
|
| Drug Interactions | 3 | 2020 | 1419 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 246 | 0.060 |
Why?
|
| Proteomics | 2 | 2015 | 3912 | 0.060 |
Why?
|
| Alendronate | 1 | 2005 | 174 | 0.060 |
Why?
|
| Etoposide | 2 | 2021 | 640 | 0.060 |
Why?
|
| Isoenzymes | 4 | 2015 | 1688 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2016 | 3573 | 0.060 |
Why?
|
| Disclosure | 1 | 2010 | 755 | 0.060 |
Why?
|
| Oleanolic Acid | 1 | 2003 | 43 | 0.060 |
Why?
|
| Methanomicrobiaceae | 1 | 2003 | 1 | 0.060 |
Why?
|
| Methanosarcinaceae | 1 | 2003 | 4 | 0.060 |
Why?
|
| Graft vs Tumor Effect | 1 | 2003 | 68 | 0.060 |
Why?
|
| Lymphoma | 3 | 2008 | 1897 | 0.060 |
Why?
|
| Quinolines | 1 | 2009 | 770 | 0.060 |
Why?
|
| Qualitative Research | 1 | 2015 | 3141 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2017 | 2508 | 0.050 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2003 | 122 | 0.050 |
Why?
|
| Alu Elements | 1 | 2004 | 115 | 0.050 |
Why?
|
| Heat-Shock Proteins | 5 | 2007 | 797 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2021 | 2058 | 0.050 |
Why?
|
| Immunoglobulin Idiotypes | 2 | 1993 | 200 | 0.050 |
Why?
|
| Electroporation | 1 | 2004 | 239 | 0.050 |
Why?
|
| Zimbabwe | 2 | 2013 | 135 | 0.050 |
Why?
|
| Calreticulin | 1 | 2024 | 115 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2003 | 662 | 0.050 |
Why?
|
| Mitochondrial Proteins | 2 | 2006 | 979 | 0.050 |
Why?
|
| Disease Models, Animal | 8 | 2017 | 18345 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2004 | 386 | 0.050 |
Why?
|
| von Willebrand Factor | 2 | 2022 | 680 | 0.050 |
Why?
|
| Aminopyridines | 2 | 2017 | 580 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2006 | 794 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 3415 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3115 | 0.050 |
Why?
|
| Melanoma | 1 | 2021 | 5706 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2018 | 6612 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2011 | 1412 | 0.050 |
Why?
|
| Counseling | 2 | 2018 | 1554 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3238 | 0.050 |
Why?
|
| Cyclins | 1 | 2005 | 605 | 0.050 |
Why?
|
| Postoperative Complications | 3 | 2015 | 15831 | 0.050 |
Why?
|
| Clavicle | 1 | 2004 | 224 | 0.050 |
Why?
|
| Case-Control Studies | 6 | 2021 | 22286 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2022 | 693 | 0.050 |
Why?
|
| Reactive Oxygen Species | 3 | 2015 | 2149 | 0.050 |
Why?
|
| Carbon | 1 | 2006 | 673 | 0.050 |
Why?
|
| alpha-2-Antiplasmin | 1 | 2022 | 13 | 0.050 |
Why?
|
| Drug Therapy | 1 | 2005 | 504 | 0.050 |
Why?
|
| Analysis of Variance | 4 | 2015 | 6225 | 0.050 |
Why?
|
| Lymphopoiesis | 1 | 2023 | 133 | 0.050 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2005 | 239 | 0.050 |
Why?
|
| Sulfonamides | 2 | 2015 | 1982 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2016 | 2061 | 0.050 |
Why?
|
| Africa | 2 | 2014 | 725 | 0.050 |
Why?
|
| Solubility | 2 | 2015 | 1083 | 0.050 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2022 | 105 | 0.050 |
Why?
|
| Health Services | 2 | 2018 | 755 | 0.050 |
Why?
|
| Amidines | 1 | 2001 | 28 | 0.050 |
Why?
|
| Evolution, Molecular | 5 | 2014 | 1896 | 0.050 |
Why?
|
| Tuberculosis | 1 | 2014 | 2029 | 0.050 |
Why?
|
| Anemia, Hemolytic | 1 | 2003 | 164 | 0.050 |
Why?
|
| Nurse Midwives | 1 | 2001 | 24 | 0.050 |
Why?
|
| Protein Kinases | 2 | 2009 | 1610 | 0.050 |
Why?
|
| beta Catenin | 1 | 2007 | 1047 | 0.050 |
Why?
|
| Acetylation | 3 | 2015 | 1055 | 0.050 |
Why?
|
| RNA | 3 | 2014 | 2718 | 0.050 |
Why?
|
| Alanine Transaminase | 2 | 2014 | 606 | 0.050 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 2744 | 0.050 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2021 | 56 | 0.050 |
Why?
|
| Recombinant Proteins | 6 | 2008 | 6515 | 0.050 |
Why?
|
| Carmustine | 3 | 2009 | 137 | 0.050 |
Why?
|
| Nurse-Patient Relations | 1 | 2001 | 101 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2009 | 2908 | 0.050 |
Why?
|
| Genes, Overlapping | 1 | 2021 | 36 | 0.050 |
Why?
|
| Myeloablative Agonists | 2 | 2015 | 210 | 0.050 |
Why?
|
| DNA | 5 | 2022 | 7213 | 0.050 |
Why?
|
| Ultrasonography, Doppler | 2 | 2019 | 463 | 0.050 |
Why?
|
| Cell Separation | 2 | 2004 | 1729 | 0.050 |
Why?
|
| Camptothecin | 1 | 2004 | 599 | 0.050 |
Why?
|
| Gene Expression Regulation | 5 | 2013 | 11930 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2022 | 257 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2021 | 68 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2002 | 472 | 0.040 |
Why?
|
| Membrane Potential, Mitochondrial | 2 | 2012 | 297 | 0.040 |
Why?
|
| Ketoprofen | 1 | 2000 | 8 | 0.040 |
Why?
|
| Heparitin Sulfate | 1 | 2022 | 223 | 0.040 |
Why?
|
| MAP Kinase Kinase 4 | 3 | 2008 | 147 | 0.040 |
Why?
|
| Oligonucleotides | 1 | 2003 | 563 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 2002 | 420 | 0.040 |
Why?
|
| Ascites | 1 | 2002 | 338 | 0.040 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2001 | 324 | 0.040 |
Why?
|
| Drug Approval | 1 | 2007 | 820 | 0.040 |
Why?
|
| Cytochromes c | 2 | 2015 | 173 | 0.040 |
Why?
|
| Structure-Activity Relationship | 3 | 2012 | 3055 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 1998 | 843 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2008 | 1409 | 0.040 |
Why?
|
| Macaca mulatta | 2 | 2017 | 2364 | 0.040 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2001 | 174 | 0.040 |
Why?
|
| Cholagogues and Choleretics | 1 | 2019 | 39 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 2003 | 693 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2003 | 892 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2002 | 832 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2012 | 169 | 0.040 |
Why?
|
| Permeability | 2 | 2012 | 725 | 0.040 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2019 | 81 | 0.040 |
Why?
|
| Phthalazines | 1 | 2002 | 397 | 0.040 |
Why?
|
| Vinblastine | 1 | 2001 | 487 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 36743 | 0.040 |
Why?
|
| Base Composition | 3 | 2004 | 291 | 0.040 |
Why?
|
| Biological Availability | 2 | 2011 | 389 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2012 | 3079 | 0.040 |
Why?
|
| Myocardium | 3 | 1998 | 4788 | 0.040 |
Why?
|
| Liver Failure, Acute | 1 | 2001 | 182 | 0.040 |
Why?
|
| Membrane Microdomains | 2 | 2015 | 205 | 0.040 |
Why?
|
| Influenza A virus | 1 | 2003 | 460 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2012 | 3965 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2011 | 1165 | 0.040 |
Why?
|
| Cold Temperature | 1 | 2003 | 791 | 0.040 |
Why?
|
| Thrombosis | 2 | 2017 | 2957 | 0.040 |
Why?
|
| Skin | 1 | 2013 | 4502 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2020 | 266 | 0.040 |
Why?
|
| Immunologic Memory | 2 | 2018 | 1378 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2009 | 1966 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2000 | 1057 | 0.040 |
Why?
|
| Osteitis Deformans | 1 | 1999 | 54 | 0.040 |
Why?
|
| Calcitonin | 1 | 2000 | 328 | 0.040 |
Why?
|
| Phylogeny | 4 | 2008 | 2843 | 0.040 |
Why?
|
| DNA Repair | 3 | 2016 | 2050 | 0.040 |
Why?
|
| CD40 Ligand | 3 | 2005 | 528 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2015 | 2487 | 0.040 |
Why?
|
| Nucleotidyltransferases | 1 | 2021 | 242 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2003 | 995 | 0.040 |
Why?
|
| Social Perception | 1 | 1983 | 435 | 0.040 |
Why?
|
| Anilides | 2 | 2016 | 413 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 9116 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2011 | 2333 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2014 | 1760 | 0.040 |
Why?
|
| Furin | 1 | 1999 | 45 | 0.040 |
Why?
|
| Mother-Child Relations | 1 | 1983 | 498 | 0.040 |
Why?
|
| Partnership Practice | 1 | 2018 | 14 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2005 | 1024 | 0.040 |
Why?
|
| Cathepsins | 2 | 2011 | 243 | 0.040 |
Why?
|
| Fractures, Spontaneous | 1 | 2000 | 232 | 0.040 |
Why?
|
| Rural Health Services | 1 | 2002 | 394 | 0.040 |
Why?
|
| Tanzania | 2 | 2013 | 1407 | 0.040 |
Why?
|
| Ibuprofen | 1 | 2000 | 229 | 0.040 |
Why?
|
| Antipsychotic Agents | 1 | 2012 | 3081 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2021 | 615 | 0.040 |
Why?
|
| Neural Conduction | 1 | 2000 | 443 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 2 | 2003 | 1082 | 0.040 |
Why?
|
| Endothelium | 1 | 2021 | 768 | 0.040 |
Why?
|
| Genomic Imprinting | 1 | 2000 | 326 | 0.040 |
Why?
|
| Family Planning Services | 1 | 2001 | 279 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 2040 | 0.040 |
Why?
|
| Acute Disease | 4 | 2012 | 7241 | 0.040 |
Why?
|
| Receptors, Interleukin-6 | 3 | 2005 | 224 | 0.040 |
Why?
|
| Tubulin | 2 | 2016 | 694 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 4168 | 0.040 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 11068 | 0.040 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1998 | 283 | 0.040 |
Why?
|
| Chemokine CCL3 | 2 | 2008 | 85 | 0.040 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2019 | 155 | 0.040 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1998 | 108 | 0.040 |
Why?
|
| Immunity | 2 | 2021 | 1004 | 0.040 |
Why?
|
| Transplantation Immunology | 1 | 2000 | 537 | 0.040 |
Why?
|
| Biotransformation | 1 | 2018 | 166 | 0.040 |
Why?
|
| Multiprotein Complexes | 2 | 2016 | 1110 | 0.040 |
Why?
|
| Substrate Specificity | 3 | 2012 | 1750 | 0.040 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2020 | 219 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 629 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 2021 | 350 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 3840 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2002 | 768 | 0.040 |
Why?
|
| Logistic Models | 4 | 2016 | 13289 | 0.040 |
Why?
|
| Stress, Psychological | 2 | 2022 | 4529 | 0.040 |
Why?
|
| Mice, Nude | 3 | 2011 | 3620 | 0.040 |
Why?
|
| DNA Replication | 3 | 2015 | 1427 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2020 | 353 | 0.040 |
Why?
|
| Denmark | 1 | 2020 | 776 | 0.040 |
Why?
|
| Fluid Therapy | 1 | 2002 | 587 | 0.040 |
Why?
|
| Constipation | 1 | 2002 | 570 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2011 | 464 | 0.040 |
Why?
|
| Rubella | 1 | 2018 | 55 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 2018 | 363 | 0.040 |
Why?
|
| Communication | 2 | 2002 | 3905 | 0.040 |
Why?
|
| Models, Econometric | 1 | 2018 | 215 | 0.040 |
Why?
|
| Thalassemia | 1 | 1998 | 267 | 0.040 |
Why?
|
| England | 1 | 2019 | 533 | 0.040 |
Why?
|
| Integrin alphaVbeta3 | 2 | 2008 | 103 | 0.040 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2021 | 620 | 0.040 |
Why?
|
| Life Tables | 3 | 2003 | 367 | 0.040 |
Why?
|
| Random Allocation | 2 | 2012 | 2396 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 1999 | 521 | 0.040 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2018 | 49 | 0.040 |
Why?
|
| Protein Subunits | 2 | 2012 | 943 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 3 | 2010 | 874 | 0.040 |
Why?
|
| Lymphoid Tissue | 1 | 2019 | 445 | 0.040 |
Why?
|
| Mumps | 1 | 2018 | 71 | 0.040 |
Why?
|
| Cell Fusion | 2 | 2010 | 294 | 0.040 |
Why?
|
| Adenosine Triphosphate | 3 | 2012 | 2004 | 0.030 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2000 | 399 | 0.030 |
Why?
|
| Sexual Behavior | 2 | 2018 | 2197 | 0.030 |
Why?
|
| Radiopharmaceuticals | 2 | 2017 | 2736 | 0.030 |
Why?
|
| Pilot Projects | 3 | 2019 | 8740 | 0.030 |
Why?
|
| Membrane Potentials | 3 | 2005 | 1091 | 0.030 |
Why?
|
| Peptides, Cyclic | 2 | 2010 | 391 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2004 | 13000 | 0.030 |
Why?
|
| Sweden | 1 | 2020 | 1382 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2000 | 602 | 0.030 |
Why?
|
| Computational Biology | 2 | 2006 | 3568 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 2 | 2007 | 186 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 406 | 0.030 |
Why?
|
| Absenteeism | 1 | 2018 | 247 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2021 | 717 | 0.030 |
Why?
|
| Neoplasm Metastasis | 6 | 2007 | 4904 | 0.030 |
Why?
|
| Autoantibodies | 2 | 2017 | 2117 | 0.030 |
Why?
|
| Endopeptidases | 1 | 2000 | 763 | 0.030 |
Why?
|
| Pyridazines | 2 | 2012 | 203 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 1999 | 794 | 0.030 |
Why?
|
| Lymnaea | 1 | 1996 | 8 | 0.030 |
Why?
|
| Genome-Wide Association Study | 2 | 2021 | 12795 | 0.030 |
Why?
|
| Chymotrypsin | 1 | 2016 | 137 | 0.030 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1998 | 264 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2003 | 1311 | 0.030 |
Why?
|
| Ligands | 3 | 2011 | 3284 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2009 | 3409 | 0.030 |
Why?
|
| Southwestern United States | 1 | 1996 | 39 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2018 | 505 | 0.030 |
Why?
|
| Brain | 3 | 2017 | 27366 | 0.030 |
Why?
|
| Mitogens | 1 | 1996 | 229 | 0.030 |
Why?
|
| Heart | 3 | 2007 | 4445 | 0.030 |
Why?
|
| Bacterial Proteins | 5 | 2008 | 3841 | 0.030 |
Why?
|
| North America | 1 | 2019 | 1289 | 0.030 |
Why?
|
| Methadone | 1 | 2018 | 317 | 0.030 |
Why?
|
| Nuclear Proteins | 3 | 2011 | 5799 | 0.030 |
Why?
|
| Free Radical Scavengers | 1 | 2016 | 213 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 716 | 0.030 |
Why?
|
| Pigment Epithelium of Eye | 1 | 1996 | 209 | 0.030 |
Why?
|
| Cross Reactions | 2 | 2015 | 828 | 0.030 |
Why?
|
| Measles | 1 | 2018 | 180 | 0.030 |
Why?
|
| Isotope Labeling | 1 | 2017 | 394 | 0.030 |
Why?
|
| Conserved Sequence | 3 | 2004 | 1162 | 0.030 |
Why?
|
| Patient Participation | 2 | 2002 | 1446 | 0.030 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 2006 | 317 | 0.030 |
Why?
|
| Open Reading Frames | 2 | 2010 | 818 | 0.030 |
Why?
|
| Osteoporosis | 1 | 2005 | 1604 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2007 | 3701 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1997 | 534 | 0.030 |
Why?
|
| Trypsin | 1 | 2016 | 491 | 0.030 |
Why?
|
| Immunoglobulin Variable Region | 2 | 1993 | 419 | 0.030 |
Why?
|
| Dithiothreitol | 1 | 2015 | 94 | 0.030 |
Why?
|
| Cell Line, Transformed | 2 | 2008 | 866 | 0.030 |
Why?
|
| Netherlands | 1 | 2020 | 2277 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2002 | 948 | 0.030 |
Why?
|
| Isomerism | 1 | 2015 | 198 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.030 |
Why?
|
| Carboplatin | 3 | 2007 | 791 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 2 | 2008 | 322 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 1998 | 376 | 0.030 |
Why?
|
| Africa, Southern | 1 | 2014 | 60 | 0.030 |
Why?
|
| Mutagens | 1 | 2015 | 181 | 0.030 |
Why?
|
| Syndecans | 2 | 2005 | 75 | 0.030 |
Why?
|
| Psychological Theory | 1 | 1996 | 173 | 0.030 |
Why?
|
| Genes, bcl-2 | 2 | 2005 | 119 | 0.030 |
Why?
|
| HIV Core Protein p24 | 1 | 2014 | 247 | 0.030 |
Why?
|
| Receptor, erbB-2 | 2 | 2005 | 2601 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2017 | 582 | 0.030 |
Why?
|
| RNA Interference | 2 | 2017 | 2830 | 0.030 |
Why?
|
| Pseudogenes | 2 | 2004 | 104 | 0.030 |
Why?
|
| Chromosomal Instability | 1 | 2015 | 176 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2015 | 364 | 0.030 |
Why?
|
| Urban Health | 1 | 1997 | 534 | 0.030 |
Why?
|
| Lymphotoxin-beta | 1 | 2014 | 14 | 0.030 |
Why?
|
| Enterovirus B, Human | 1 | 1994 | 49 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2018 | 1533 | 0.030 |
Why?
|
| Oximes | 1 | 2015 | 303 | 0.030 |
Why?
|
| Amino Acid Sequence | 6 | 2004 | 13420 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2004 | 3585 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2018 | 996 | 0.030 |
Why?
|
| HIV-2 | 1 | 2014 | 156 | 0.030 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 1993 | 7 | 0.030 |
Why?
|
| Neurites | 1 | 1996 | 389 | 0.030 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 15443 | 0.030 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2014 | 133 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2015 | 393 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2014 | 126 | 0.030 |
Why?
|
| Epidemiologic Methods | 2 | 2008 | 1326 | 0.030 |
Why?
|
| Spinal Fractures | 1 | 2000 | 710 | 0.030 |
Why?
|
| Rhodamine 123 | 1 | 2013 | 37 | 0.030 |
Why?
|
| Pyridines | 2 | 2002 | 2893 | 0.030 |
Why?
|
| Phase Transition | 1 | 2013 | 70 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2014 | 145 | 0.030 |
Why?
|
| Internet | 1 | 2006 | 3111 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2015 | 591 | 0.030 |
Why?
|
| Carotid Artery Injuries | 1 | 1994 | 96 | 0.030 |
Why?
|
| Hip Fractures | 1 | 2002 | 997 | 0.030 |
Why?
|
| Stem Cell Niche | 1 | 2016 | 347 | 0.030 |
Why?
|
| Immunity, Cellular | 2 | 2013 | 1561 | 0.030 |
Why?
|
| Antigens, Nuclear | 1 | 2014 | 182 | 0.030 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2014 | 199 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2003 | 2748 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2012 | 6983 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2017 | 517 | 0.030 |
Why?
|
| Antigen-Antibody Complex | 1 | 1995 | 513 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2017 | 2299 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2015 | 711 | 0.030 |
Why?
|
| Paracrine Communication | 2 | 2006 | 278 | 0.030 |
Why?
|
| DNA Primers | 2 | 2014 | 2827 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2012 | 31 | 0.030 |
Why?
|
| SEER Program | 1 | 2018 | 1444 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2015 | 382 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 1753 | 0.030 |
Why?
|
| Solutions | 1 | 2013 | 409 | 0.030 |
Why?
|
| Melena | 1 | 2012 | 32 | 0.030 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2013 | 237 | 0.030 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2012 | 68 | 0.030 |
Why?
|
| Heart Failure | 1 | 2017 | 11884 | 0.030 |
Why?
|
| Buffers | 1 | 2012 | 143 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 2015 | 610 | 0.030 |
Why?
|
| Microsatellite Repeats | 2 | 2010 | 784 | 0.030 |
Why?
|
| Genes, Immunoglobulin | 1 | 1993 | 283 | 0.030 |
Why?
|
| Sulfones | 1 | 2015 | 448 | 0.030 |
Why?
|
| Mutation, Missense | 2 | 2014 | 2592 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 2029 | 0.030 |
Why?
|
| Lipopolysaccharides | 2 | 2013 | 2219 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2021 | 2574 | 0.030 |
Why?
|
| Leukapheresis | 2 | 2004 | 150 | 0.030 |
Why?
|
| Biological Assay | 1 | 2015 | 627 | 0.020 |
Why?
|
| Ventilator Weaning | 1 | 2013 | 170 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 2 | 2011 | 3771 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2005 | 384 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2012 | 61 | 0.020 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2012 | 42 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 2 | 2014 | 4414 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 2 | 2014 | 2011 | 0.020 |
Why?
|
| Oxazines | 1 | 2014 | 358 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2002 | 1662 | 0.020 |
Why?
|
| Syndrome | 1 | 2018 | 3272 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2004 | 511 | 0.020 |
Why?
|
| B-Lymphocyte Subsets | 1 | 1993 | 240 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2000 | 1080 | 0.020 |
Why?
|
| Hydrogen Bonding | 1 | 2012 | 289 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 4114 | 0.020 |
Why?
|
| Texas | 1 | 2013 | 410 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 874 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2019 | 1078 | 0.020 |
Why?
|
| Sulfoxides | 1 | 2011 | 47 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 3 | 2004 | 2634 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2010 | 18069 | 0.020 |
Why?
|
| Genome, Human | 2 | 2004 | 4443 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2013 | 300 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2015 | 960 | 0.020 |
Why?
|
| Ligation | 1 | 2012 | 446 | 0.020 |
Why?
|
| eIF-2 Kinase | 1 | 2012 | 147 | 0.020 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2014 | 309 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2012 | 125 | 0.020 |
Why?
|
| Diketopiperazines | 1 | 2011 | 24 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 378 | 0.020 |
Why?
|
| Crystallization | 1 | 2012 | 520 | 0.020 |
Why?
|
| Methotrexate | 2 | 2012 | 1721 | 0.020 |
Why?
|
| Androgens | 2 | 2011 | 1281 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2018 | 1308 | 0.020 |
Why?
|
| Interleukins | 2 | 2004 | 796 | 0.020 |
Why?
|
| Tracheal Stenosis | 1 | 2013 | 228 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2012 | 612 | 0.020 |
Why?
|
| Base Sequence | 4 | 2008 | 12417 | 0.020 |
Why?
|
| Trans-Activators | 3 | 2008 | 2857 | 0.020 |
Why?
|
| Pakistan | 1 | 2012 | 299 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2005 | 627 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 2012 | 383 | 0.020 |
Why?
|
| Proteoglycans | 2 | 2005 | 809 | 0.020 |
Why?
|
| Alleles | 2 | 2014 | 6894 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2013 | 609 | 0.020 |
Why?
|
| Lysine | 1 | 2015 | 1000 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 951 | 0.020 |
Why?
|
| Azathioprine | 1 | 2012 | 354 | 0.020 |
Why?
|
| Databases, Genetic | 2 | 2010 | 1758 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2012 | 540 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2011 | 351 | 0.020 |
Why?
|
| Leukemia, Lymphoid | 2 | 1988 | 311 | 0.020 |
Why?
|
| Cell Fractionation | 1 | 2011 | 247 | 0.020 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 1990 | 74 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2015 | 620 | 0.020 |
Why?
|
| Lovastatin | 1 | 1990 | 115 | 0.020 |
Why?
|
| Esophagoscopy | 1 | 2012 | 398 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 20218 | 0.020 |
Why?
|
| Cardiomegaly | 1 | 1993 | 591 | 0.020 |
Why?
|
| Epigenomics | 1 | 2016 | 959 | 0.020 |
Why?
|
| Endoscopy, Digestive System | 1 | 2013 | 358 | 0.020 |
Why?
|
| Back Pain | 1 | 2014 | 547 | 0.020 |
Why?
|
| Contig Mapping | 1 | 2010 | 56 | 0.020 |
Why?
|
| Interleukin-4 | 3 | 2003 | 1157 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2014 | 736 | 0.020 |
Why?
|
| K562 Cells | 1 | 2012 | 644 | 0.020 |
Why?
|
| Models, Animal | 2 | 2007 | 2121 | 0.020 |
Why?
|
| Caregivers | 1 | 2022 | 2302 | 0.020 |
Why?
|
| Hypertension, Portal | 1 | 2012 | 230 | 0.020 |
Why?
|
| Unfolded Protein Response | 1 | 2012 | 239 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2010 | 2801 | 0.020 |
Why?
|
| Thiotepa | 2 | 2002 | 66 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 1793 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2015 | 1023 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2543 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2010 | 162 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 1816 | 0.020 |
Why?
|
| Genetics, Medical | 2 | 2004 | 334 | 0.020 |
Why?
|
| Paclitaxel | 3 | 2002 | 1728 | 0.020 |
Why?
|
| Diagnostic Imaging | 2 | 2015 | 3533 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2015 | 1094 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2003 | 560 | 0.020 |
Why?
|
| Tyrosine | 2 | 2004 | 1427 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2010 | 424 | 0.020 |
Why?
|
| Plasminogen | 1 | 2009 | 144 | 0.020 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2009 | 32 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2010 | 178 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2010 | 190 | 0.020 |
Why?
|
| Mastectomy | 1 | 1998 | 1861 | 0.020 |
Why?
|
| Antibodies, Protozoan | 1 | 2010 | 251 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 2 | 2007 | 1133 | 0.020 |
Why?
|
| Tuberous Sclerosis | 1 | 1997 | 1042 | 0.020 |
Why?
|
| Ubiquinone | 1 | 1990 | 181 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 1196 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2009 | 53 | 0.020 |
Why?
|
| Hospitalization | 2 | 2020 | 10843 | 0.020 |
Why?
|
| Models, Statistical | 2 | 2016 | 5109 | 0.020 |
Why?
|
| Observer Variation | 1 | 2015 | 2618 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2002 | 3269 | 0.020 |
Why?
|
| Africa South of the Sahara | 1 | 2011 | 752 | 0.020 |
Why?
|
| Cell Size | 2 | 2004 | 626 | 0.020 |
Why?
|
| Phenotype | 3 | 2003 | 16723 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 1512 | 0.020 |
Why?
|
| Urochordata | 1 | 2008 | 19 | 0.020 |
Why?
|
| Janus Kinases | 1 | 2010 | 253 | 0.020 |
Why?
|
| Hepatorenal Syndrome | 1 | 2009 | 76 | 0.020 |
Why?
|
| Periodontal Pocket | 1 | 2009 | 174 | 0.020 |
Why?
|
| Cathepsin K | 1 | 2008 | 65 | 0.020 |
Why?
|
| Biological Transport | 1 | 2013 | 2085 | 0.020 |
Why?
|
| Milk, Human | 1 | 2013 | 490 | 0.020 |
Why?
|
| Software | 1 | 2002 | 4479 | 0.020 |
Why?
|
| Inpatients | 1 | 2020 | 2571 | 0.020 |
Why?
|
| Antigens, Protozoan | 1 | 2010 | 315 | 0.020 |
Why?
|
| Kinetics | 1 | 2016 | 6328 | 0.020 |
Why?
|
| Methods | 1 | 2008 | 1066 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2008 | 171 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2011 | 325 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2009 | 2916 | 0.020 |
Why?
|
| Genotype | 2 | 2013 | 13042 | 0.020 |
Why?
|
| Gene Order | 1 | 2008 | 166 | 0.020 |
Why?
|
| Sequence Homology | 1 | 2008 | 197 | 0.020 |
Why?
|
| Boston | 1 | 2021 | 9368 | 0.020 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2012 | 302 | 0.020 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2004 | 606 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2008 | 109 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2023 | 9384 | 0.020 |
Why?
|
| Interferons | 1 | 2012 | 720 | 0.020 |
Why?
|
| Actins | 1 | 2015 | 2064 | 0.020 |
Why?
|
| Depression, Chemical | 1 | 2007 | 186 | 0.020 |
Why?
|
| Affect | 1 | 1996 | 1495 | 0.020 |
Why?
|
| Chemokines | 1 | 2012 | 963 | 0.020 |
Why?
|
| CpG Islands | 2 | 2004 | 1206 | 0.020 |
Why?
|
| Hypercalcemia | 1 | 2011 | 424 | 0.020 |
Why?
|
| Chemokine CCL4 | 1 | 2007 | 127 | 0.020 |
Why?
|
| Repressor Proteins | 2 | 2015 | 2982 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 3044 | 0.020 |
Why?
|
| E-Selectin | 1 | 2010 | 577 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1999 | 8120 | 0.020 |
Why?
|
| Self Report | 1 | 2019 | 3773 | 0.020 |
Why?
|
| Israel | 1 | 2010 | 726 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 2007 | 141 | 0.020 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2007 | 122 | 0.020 |
Why?
|
| Osteoprotegerin | 1 | 2008 | 179 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 567 | 0.020 |
Why?
|
| Tooth Extraction | 1 | 2009 | 225 | 0.020 |
Why?
|
| Cytokinins | 1 | 2007 | 25 | 0.020 |
Why?
|
| Deglutition Disorders | 1 | 2013 | 640 | 0.020 |
Why?
|
| Triamcinolone Acetonide | 1 | 2008 | 105 | 0.020 |
Why?
|
| Etodolac | 1 | 2007 | 19 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 4248 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2015 | 1430 | 0.020 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1994 | 807 | 0.020 |
Why?
|
| Bone Density | 1 | 2000 | 3573 | 0.020 |
Why?
|
| Antioxidants | 1 | 2015 | 1674 | 0.020 |
Why?
|
| Quality of Health Care | 2 | 2018 | 4310 | 0.020 |
Why?
|
| Dogs | 1 | 2012 | 3843 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 3 | 2007 | 6070 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2012 | 1008 | 0.020 |
Why?
|
| Chromosomes, Bacterial | 1 | 2008 | 281 | 0.020 |
Why?
|
| Thrombin | 1 | 2009 | 600 | 0.020 |
Why?
|
| Photosynthesis | 1 | 2007 | 69 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 2008 | 214 | 0.020 |
Why?
|
| RNA, Plant | 1 | 2006 | 30 | 0.020 |
Why?
|
| Plant Roots | 1 | 2007 | 122 | 0.020 |
Why?
|
| Estrogens | 2 | 2005 | 1536 | 0.020 |
Why?
|
| Fetal Blood | 1 | 2014 | 1361 | 0.020 |
Why?
|
| Ethanol | 1 | 1993 | 1331 | 0.020 |
Why?
|
| Temperature | 1 | 2013 | 2234 | 0.020 |
Why?
|
| Species Specificity | 2 | 2001 | 2414 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2007 | 200 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2013 | 1880 | 0.020 |
Why?
|
| DNA, Archaeal | 1 | 2006 | 8 | 0.020 |
Why?
|
| Food Microbiology | 1 | 2006 | 74 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2013 | 1442 | 0.020 |
Why?
|
| Marine Biology | 1 | 2006 | 17 | 0.020 |
Why?
|
| Time | 1 | 2008 | 552 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2009 | 600 | 0.020 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2011 | 628 | 0.020 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2006 | 66 | 0.020 |
Why?
|
| Genes, Plant | 1 | 2006 | 128 | 0.020 |
Why?
|
| Myocarditis | 1 | 1994 | 802 | 0.020 |
Why?
|
| Synapses | 1 | 1996 | 1765 | 0.020 |
Why?
|
| Oceans and Seas | 1 | 2006 | 47 | 0.020 |
Why?
|
| Depression | 2 | 2022 | 8231 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2009 | 892 | 0.020 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 2006 | 34 | 0.020 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2006 | 72 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2015 | 6338 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 11519 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2009 | 582 | 0.020 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2007 | 167 | 0.020 |
Why?
|
| Neoplasms, Experimental | 2 | 2002 | 1230 | 0.020 |
Why?
|
| Chorioallantoic Membrane | 1 | 2006 | 50 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2007 | 382 | 0.020 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2006 | 148 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 1993 | 2094 | 0.020 |
Why?
|
| Bleomycin | 1 | 2007 | 492 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2017 | 1983 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 1377 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2010 | 904 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2007 | 345 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 1788 | 0.020 |
Why?
|
| Cell Transformation, Viral | 2 | 2003 | 530 | 0.020 |
Why?
|
| Molecular Mimicry | 1 | 2006 | 213 | 0.020 |
Why?
|
| Somatomedins | 1 | 2006 | 179 | 0.020 |
Why?
|
| Stem Cells | 2 | 2010 | 3537 | 0.020 |
Why?
|
| Angiopoietin-1 | 1 | 2006 | 133 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 1168 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 1752 | 0.020 |
Why?
|
| raf Kinases | 1 | 2005 | 117 | 0.020 |
Why?
|
| cdc25 Phosphatases | 1 | 2005 | 60 | 0.020 |
Why?
|
| International Cooperation | 1 | 2012 | 1434 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2011 | 1138 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2005 | 342 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2009 | 671 | 0.020 |
Why?
|
| Operon | 1 | 2006 | 371 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 876 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 2005 | 305 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 361 | 0.020 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2004 | 39 | 0.020 |
Why?
|
| Body Weight | 1 | 1996 | 4628 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2010 | 1042 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2013 | 1929 | 0.010 |
Why?
|
| G2 Phase | 1 | 2005 | 134 | 0.010 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2004 | 72 | 0.010 |
Why?
|
| Synteny | 1 | 2004 | 77 | 0.010 |
Why?
|
| Citric Acid Cycle | 1 | 2006 | 234 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 2000 | 13500 | 0.010 |
Why?
|
| Electrocardiography | 2 | 2017 | 6411 | 0.010 |
Why?
|
| Stroke | 1 | 2007 | 9755 | 0.010 |
Why?
|
| Angiopoietin-2 | 1 | 2006 | 186 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2013 | 2871 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 829 | 0.010 |
Why?
|
| GABA-A Receptor Antagonists | 1 | 2004 | 59 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2014 | 3402 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2004 | 148 | 0.010 |
Why?
|
| Plasmids | 2 | 2005 | 2269 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 294 | 0.010 |
Why?
|
| Monitoring, Immunologic | 1 | 2004 | 100 | 0.010 |
Why?
|
| Sick Role | 1 | 2005 | 229 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2005 | 281 | 0.010 |
Why?
|
| CDC2 Protein Kinase | 1 | 2005 | 212 | 0.010 |
Why?
|
| Pan troglodytes | 1 | 2004 | 224 | 0.010 |
Why?
|
| Contactins | 1 | 2003 | 21 | 0.010 |
Why?
|
| Plant Proteins | 1 | 2006 | 376 | 0.010 |
Why?
|
| Phosphoric Acids | 1 | 2003 | 19 | 0.010 |
Why?
|
| Clone Cells | 1 | 2007 | 1669 | 0.010 |
Why?
|
| Caspase 7 | 1 | 2003 | 51 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 1546 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 610 | 0.010 |
Why?
|
| Protein Binding | 2 | 2008 | 9343 | 0.010 |
Why?
|
| Euchromatin | 1 | 2004 | 54 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2015 | 3140 | 0.010 |
Why?
|
| Contrast Media | 1 | 2017 | 5331 | 0.010 |
Why?
|
| Anthracenes | 1 | 2003 | 83 | 0.010 |
Why?
|
| Erythropoietin | 1 | 2008 | 718 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 2004 | 421 | 0.010 |
Why?
|
| Chick Embryo | 1 | 2006 | 975 | 0.010 |
Why?
|
| Genes, Archaeal | 1 | 2003 | 8 | 0.010 |
Why?
|
| Oxidoreductases | 1 | 2006 | 410 | 0.010 |
Why?
|
| Galectin 3 | 1 | 2005 | 240 | 0.010 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2008 | 800 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 2202 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 2004 | 320 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2008 | 667 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2010 | 2602 | 0.010 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2005 | 430 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 2007 | 1076 | 0.010 |
Why?
|
| Archaeal Proteins | 1 | 2003 | 57 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 564 | 0.010 |
Why?
|
| Sphingosine | 1 | 2005 | 307 | 0.010 |
Why?
|
| Vertebrates | 1 | 2004 | 227 | 0.010 |
Why?
|
| Histidine | 1 | 2004 | 301 | 0.010 |
Why?
|
| Receptor Cross-Talk | 1 | 2003 | 118 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 1667 | 0.010 |
Why?
|
| Population Surveillance | 1 | 1993 | 2594 | 0.010 |
Why?
|
| Superoxides | 1 | 2004 | 389 | 0.010 |
Why?
|
| Arabidopsis | 1 | 2006 | 466 | 0.010 |
Why?
|
| Physician's Role | 1 | 2010 | 925 | 0.010 |
Why?
|
| RNA, Untranslated | 1 | 2006 | 455 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 2004 | 255 | 0.010 |
Why?
|
| Ribosomal Proteins | 1 | 2005 | 369 | 0.010 |
Why?
|
| Reference Values | 2 | 2000 | 4938 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 816 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 2005 | 684 | 0.010 |
Why?
|
| Cattle | 1 | 2008 | 3816 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2004 | 717 | 0.010 |
Why?
|
| NFATC Transcription Factors | 1 | 2005 | 393 | 0.010 |
Why?
|
| Isoquinolines | 1 | 2004 | 354 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 5536 | 0.010 |
Why?
|
| Pharmacogenetics | 1 | 2006 | 682 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2004 | 1142 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 123 | 0.010 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 1560 | 0.010 |
Why?
|
| Role | 1 | 1983 | 176 | 0.010 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2002 | 111 | 0.010 |
Why?
|
| Phosphoserine | 1 | 2002 | 204 | 0.010 |
Why?
|
| Immunodominant Epitopes | 1 | 2003 | 244 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 1988 | 1150 | 0.010 |
Why?
|
| Probability | 1 | 2007 | 2479 | 0.010 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2001 | 50 | 0.010 |
Why?
|
| bcl-Associated Death Protein | 1 | 2002 | 102 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2002 | 118 | 0.010 |
Why?
|
| Central Venous Pressure | 1 | 2002 | 80 | 0.010 |
Why?
|
| Hepatitis B | 1 | 2007 | 711 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 7851 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 2004 | 539 | 0.010 |
Why?
|
| Nursing Methodology Research | 1 | 2001 | 64 | 0.010 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2001 | 42 | 0.010 |
Why?
|
| Tape Recording | 1 | 2001 | 77 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2012 | 6029 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2002 | 455 | 0.010 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1993 | 1642 | 0.010 |
Why?
|
| Blood | 1 | 2004 | 599 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 2227 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 2003 | 605 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2003 | 252 | 0.010 |
Why?
|
| Genome | 1 | 2010 | 1754 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2019 | 4884 | 0.010 |
Why?
|
| Amiloride | 1 | 2001 | 116 | 0.010 |
Why?
|
| Aspartic Acid | 1 | 2004 | 577 | 0.010 |
Why?
|
| GC Rich Sequence | 1 | 2001 | 19 | 0.010 |
Why?
|
| Integrin alpha4 | 1 | 2001 | 88 | 0.010 |
Why?
|
| Emotions | 2 | 2005 | 2766 | 0.010 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2001 | 106 | 0.010 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2004 | 260 | 0.010 |
Why?
|
| RNA, Transfer | 1 | 2003 | 284 | 0.010 |
Why?
|
| Glioma | 1 | 2016 | 3503 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2007 | 1613 | 0.010 |
Why?
|
| Lymphopenia | 1 | 1983 | 300 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2001 | 205 | 0.010 |
Why?
|
| Social Change | 1 | 2001 | 152 | 0.010 |
Why?
|
| Cornea | 1 | 2008 | 1316 | 0.010 |
Why?
|
| Multigene Family | 1 | 2004 | 1081 | 0.010 |
Why?
|
| Necrosis | 1 | 2005 | 1616 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2011 | 2235 | 0.010 |
Why?
|
| Biological Evolution | 1 | 2006 | 1076 | 0.010 |
Why?
|
| Antigens | 1 | 1986 | 1442 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 2000 | 165 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 2000 | 114 | 0.010 |
Why?
|
| Molecular Weight | 2 | 1997 | 2173 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2003 | 921 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 1993 | 647 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1990 | 2846 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 1396 | 0.010 |
Why?
|
| Mexico | 1 | 2002 | 769 | 0.010 |
Why?
|
| Cricetinae | 1 | 2004 | 2423 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 2000 | 134 | 0.010 |
Why?
|
| Mechlorethamine | 1 | 2000 | 129 | 0.010 |
Why?
|
| Self-Assessment | 1 | 2002 | 400 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2002 | 457 | 0.010 |
Why?
|
| Stomach Ulcer | 1 | 2000 | 118 | 0.010 |
Why?
|
| Serine | 1 | 2004 | 831 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2001 | 381 | 0.010 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2002 | 309 | 0.010 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2001 | 252 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2007 | 1739 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2002 | 610 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 1438 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 2227 | 0.010 |
Why?
|
| Fibronectins | 1 | 2003 | 722 | 0.010 |
Why?
|
| Medicare | 1 | 2018 | 6814 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 2 | 2005 | 6232 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2010 | 3448 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2002 | 517 | 0.010 |
Why?
|
| Cadherins | 1 | 2004 | 904 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 2003 | 899 | 0.010 |
Why?
|
| Microcomputers | 1 | 2000 | 139 | 0.010 |
Why?
|
| Self Medication | 1 | 2000 | 115 | 0.010 |
Why?
|
| Life Change Events | 1 | 2005 | 960 | 0.010 |
Why?
|
| Hydroxyproline | 1 | 1999 | 110 | 0.010 |
Why?
|
| Fracture Fixation | 1 | 2002 | 370 | 0.010 |
Why?
|
| Public Sector | 1 | 2001 | 266 | 0.010 |
Why?
|
| Philadelphia | 1 | 2000 | 271 | 0.010 |
Why?
|
| Warfarin | 1 | 2007 | 1493 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2000 | 915 | 0.010 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2002 | 409 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2007 | 1671 | 0.010 |
Why?
|
| Prostaglandins | 1 | 2000 | 398 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2001 | 794 | 0.010 |
Why?
|
| Amino Acids | 1 | 2005 | 1716 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2001 | 781 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2001 | 587 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2004 | 1104 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 2005 | 1804 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 1995 | 0.010 |
Why?
|
| Protein Folding | 1 | 2002 | 871 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2002 | 1526 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2000 | 1550 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2002 | 723 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2004 | 1251 | 0.010 |
Why?
|
| Protein Transport | 1 | 2004 | 1951 | 0.010 |
Why?
|
| Endoscopy | 1 | 2008 | 1854 | 0.010 |
Why?
|
| Nasal Cavity | 1 | 2000 | 310 | 0.010 |
Why?
|
| Personal Satisfaction | 1 | 1983 | 643 | 0.010 |
Why?
|
| Skin Tests | 1 | 2000 | 630 | 0.010 |
Why?
|
| Flavonoids | 1 | 2001 | 447 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2012 | 3977 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 4415 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 2000 | 234 | 0.010 |
Why?
|
| Private Sector | 1 | 2001 | 396 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2004 | 3074 | 0.010 |
Why?
|
| Progesterone | 1 | 2002 | 752 | 0.010 |
Why?
|
| Hepatitis C | 1 | 2007 | 1594 | 0.010 |
Why?
|
| Automation | 1 | 2000 | 589 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2003 | 1530 | 0.010 |
Why?
|
| Telomere | 1 | 2003 | 943 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 1327 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2001 | 2178 | 0.010 |
Why?
|
| DNA Transposable Elements | 1 | 2001 | 764 | 0.010 |
Why?
|
| Child Behavior | 1 | 1983 | 864 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1988 | 1930 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2001 | 1207 | 0.010 |
Why?
|
| Mucin-1 | 1 | 2001 | 536 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 1892 | 0.010 |
Why?
|
| Ciliary Neurotrophic Factor | 1 | 1996 | 77 | 0.010 |
Why?
|
| Thiazoles | 1 | 2003 | 1542 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 1983 | 2742 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2002 | 1625 | 0.010 |
Why?
|
| Health Services Research | 1 | 2002 | 1815 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2008 | 2599 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 4915 | 0.010 |
Why?
|
| Anesthesia, General | 1 | 2002 | 1188 | 0.010 |
Why?
|
| Liposomes | 1 | 1998 | 790 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2003 | 1889 | 0.010 |
Why?
|
| Culture Media | 1 | 1996 | 898 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2000 | 1474 | 0.010 |
Why?
|
| Educational Status | 1 | 2001 | 2514 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2005 | 2662 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2000 | 2108 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1998 | 708 | 0.010 |
Why?
|
| Graft Survival | 1 | 2004 | 3894 | 0.010 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1993 | 158 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 22381 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2003 | 1399 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1996 | 1265 | 0.010 |
Why?
|
| Binding Sites | 1 | 2001 | 6022 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2001 | 2118 | 0.010 |
Why?
|
| Exons | 1 | 1997 | 2393 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2001 | 2337 | 0.010 |
Why?
|
| Carotid Artery, Internal | 1 | 1994 | 440 | 0.010 |
Why?
|
| Interneurons | 1 | 1996 | 591 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1998 | 1501 | 0.010 |
Why?
|
| Motor Neurons | 1 | 1996 | 870 | 0.010 |
Why?
|
| Oncogene Proteins v-rel | 1 | 1990 | 8 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2008 | 5520 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1990 | 849 | 0.010 |
Why?
|
| Anxiety | 1 | 2005 | 4672 | 0.010 |
Why?
|
| Hyperthyroidism | 1 | 1971 | 292 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1998 | 2204 | 0.010 |
Why?
|
| Proto-Oncogenes | 1 | 1990 | 321 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 1993 | 1888 | 0.000 |
Why?
|
| Carrier Proteins | 1 | 2002 | 4937 | 0.000 |
Why?
|
| Mass Screening | 1 | 2005 | 5458 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 11101 | 0.000 |
Why?
|
| Cardiomyopathies | 1 | 2001 | 2058 | 0.000 |
Why?
|
| Dopamine | 1 | 1996 | 1592 | 0.000 |
Why?
|
| Ionomycin | 1 | 1988 | 110 | 0.000 |
Why?
|
| Chickens | 1 | 1990 | 845 | 0.000 |
Why?
|
| Cardiac Output | 1 | 1990 | 838 | 0.000 |
Why?
|
| Ethers | 1 | 1988 | 73 | 0.000 |
Why?
|
| Length of Stay | 1 | 2002 | 6495 | 0.000 |
Why?
|
| Interleukin-5 | 1 | 1988 | 267 | 0.000 |
Why?
|
| Mycobacterium bovis | 1 | 1988 | 148 | 0.000 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1988 | 826 | 0.000 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2005 | 4640 | 0.000 |
Why?
|
| Palatine Tonsil | 1 | 1986 | 193 | 0.000 |
Why?
|
| Blood Platelets | 1 | 1996 | 2477 | 0.000 |
Why?
|
| Myocardial Contraction | 1 | 1990 | 1525 | 0.000 |
Why?
|
| Longitudinal Studies | 1 | 2002 | 14785 | 0.000 |
Why?
|
| Interleukin-1 | 1 | 1988 | 1252 | 0.000 |
Why?
|
| Lymphocytes, Null | 1 | 1983 | 13 | 0.000 |
Why?
|
| Immunoglobulin Allotypes | 1 | 1983 | 52 | 0.000 |
Why?
|
| Rosette Formation | 1 | 1983 | 152 | 0.000 |
Why?
|
| Hypercholesterolemia | 1 | 1990 | 1145 | 0.000 |
Why?
|
| Antigens, Surface | 1 | 1988 | 1617 | 0.000 |
Why?
|
| Thymus Gland | 1 | 1986 | 1266 | 0.000 |
Why?
|
| Drosophila melanogaster | 1 | 1990 | 1726 | 0.000 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1983 | 547 | 0.000 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1990 | 2680 | 0.000 |
Why?
|
| Escherichia coli | 1 | 1990 | 4215 | 0.000 |
Why?
|
| Stroke Volume | 1 | 1990 | 5625 | 0.000 |
Why?
|
| Coronary Disease | 1 | 1990 | 5919 | 0.000 |
Why?
|
| Carbimazole | 1 | 1971 | 4 | 0.000 |
Why?
|
| Thyroid Function Tests | 1 | 1971 | 289 | 0.000 |
Why?
|
| Propranolol | 1 | 1971 | 493 | 0.000 |
Why?
|
| Mitral Valve Stenosis | 1 | 1971 | 342 | 0.000 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1971 | 1415 | 0.000 |
Why?
|
| Atrial Fibrillation | 1 | 1971 | 5182 | 0.000 |
Why?
|
| Hypertension | 1 | 1971 | 8616 | 0.000 |
Why?
|